

REMARKS

I. Status of the Claims

Claims 45-61 are pending in this application.

Claim 54 has been amended to recite an “isolated” nucleic acid to distinguish the claimed nucleic acid molecule to any molecule that might exist naturally in a non-isolated form. Support for this amendment can be found throughout the specification, including, for example, at page 14, lines 12-21. The specification has also been amended at pages 23-24 to insert the SEQ ID NOs corresponding to the known sequences deposited at GenBank under the Accession Nos AE00159, AE000350, and J01713 and referenced at pages 23-24 of the specification.

This amendment does not add any new matter.

II. Objection to Specification

The Office objects to the amendment filed 2 November 2006 under 35 U.S.C. §132(a) alleging that it introduces new matter into the disclosure. Office Action at 2. According to the Office, the “additional matter which is not supported by the original disclosure is as follows: SEQ ID NOs 14-16.” *Id.* The Office further asserts that if the sequences

are the GenBank Accession Nos. referenced on pages 23 and 24 of the specification, in the context of the specification the Accession Nos. are used only to indicate where within the Accession Nos the specific primers in the PCR anneal, it is not even disclosed that the Accession Nos. were the actual PCR template (e.g. page 23, lines 19-26). Hence, the only support found for any sequences from these Accession Nos. is the inherent support that the PCR primers used in the specification anneal at specific regions in the Accession Nos. This does not provide support for the entire Accession Nos. which, at best, appear to be what is contained in the Sequence Listing.

Id.

Applicant respectfully traverses this objection. As noted by the Office, SEQ ID NOs 14, 15, and 16 correspond to the sequences deposited at GenBank under the Accession Nos AE00159, AE000350, and J01713, respectively. Pages 23-24 of the specification disclose that individual tRNA genes were isolated by PCR using primers that anneal at specific base pairs in the GenBank sequences AE00159, AE000350, and J01713. Thus, pages 23-24 teach one way to isolate *E. coli* tRNA genes using known nucleic acid sequences deposited and accessible from GenBank. Applicant's reference to these sequences by their Accession numbers provides an acceptable, short hand notation for referring to *known* nucleic acid sequences that complies with the written description requirement of 35 U.S.C. §112.

The Office's position that including the sequences of AE00159, AE000350, and J01713 in the sequence listing somehow introduces new matter into the specification because Applicant did not also set forth in the specification the known nucleotide sequences of AE00159, AE000350, and J01713 exalts form over substance and is directly at odds with Federal Circuit precedence on this issue. "Indeed, a requirement that patentees recite known DNA structures, if one existed, would serve no goal of the written description requirement. It would neither enforce the quid pro quo between the patentee and the public by forcing the disclosure of new information, nor would it be necessary to demonstrate to a person of ordinary skill in the art that the patentee was in possession of the claimed invention." *Falko-Gunter Falkner v. Inglis*, 448 F.3d 1357, 1368 (Fed. Cir. 2006). In *Falko-Gunter Falkner*, the Federal Circuit held that "where, as in this case, accessible literature sources clearly provided, as of the relevant date, genes and their nucleotide sequences . . ., satisfaction of the written description requirement does not require either the recitation or incorporation by reference (where permitted) of such genes and sequences." *Id.* Accordingly, SEQ ID NOs 14-16, corresponding to nucleotide sequences

referenced in the specification and accessible from literature sources (GenBank; *see also* Blattner *et al.*, Science 277(5331):1453-1474 (1997); Nakajima *et al.*, Cell 23(1):239-249 (1981)) as of the priority date, do not constitute new matter and do not require either the recitation or incorporation by reference of the specific nucleotide sequences. For these reasons, Applicant respectfully requests that the Office withdraw the objection to the amendment filed 2 November 2006 under 35 U.S.C. §132(a).

III. Rejections Under 35 U.S.C. §112, Second Paragraph

The Office rejects claims 50-52 and 59-61 under 35 U.S.C. §112, second paragraph, as allegedly “indefinite for failing to particularly point out and distinctly claim the subject matter the applicant regards as the invention.” Office Action at 3. More specifically, the Office asserts:

Claims 50-52 and 59-61 recite tRNA sequences comprising sequences found between specific base pairs of Genbank Accession Nos. The specification provides no guidance on which, if any, of the SEQ ID NOS in the Sequence Listing corresponds to the Genbank Accession Nos. recited in the claims.

Id. Applicant respectfully traverses this rejection.

Applicant has amended the specification at pages 23 and 24 to indicate that SEQ ID NO 14 corresponds to AE000159; SEQ ID NO:15 corresponds to AE000350; and J01713 corresponds to SEQ ID NO:16.

The Office also asserts that

because the content of Genbank entries can (and do) change over time due to corrections, it cannot be determined if the sequences represented by the SEQ ID NOS (if they are the recited Genbank Nos.) are the actual DNA sequences as they existed at the time of filing of the instant application (applicants claim priority to 1999). Therefore, it cannot be determined what the actual tRNA sequences must be in order to anticipate the claims, preventing a satisfactory search of the claims.

Id.

Applicant acknowledges that GenBank entries can change over time due, for example, to corrections of the sequence. However, GenBank inserts warnings in its entries to alert readers when a sequence has changed as well as interactive links to find the altered sequence. For example, the GenBank entry for Accession No. AE000159 indicates that the sequence was replaced on 21 June 2004 by gi:48994873. *See* Attachment A. Thus, the 10,133 base pair sequence at Accession No. AE1000159, represented by SEQ ID NO:14, corresponds to the sequence as submitted and as it existed as of Applicant's priority date. The GenBank entry for Accession No. AE000350 indicates that the sequence replaced gi:178900 on 9 September 1997. *See* Attachment B. There is no indication that the sequence ever changed after 9 September 1997. Thus, the 10,401 base pair sequence at Accession No. AE1000350, represented by SEQ ID NO:15, corresponds to the sequence as it existed as of Applicant's priority date. Finally, the GenBank entry for Accession No. J01713 indicates that the 1100 base pair sequence has not changed since its submission. *See* Attachment C. Thus, the 1100 base pair sequence at Accession No. J01713, represented by SEQ ID NO:16, corresponds to the sequence as submitted and as it existed as of Applicant's priority date.

As evidenced by Attachments A-C, as of Applicant's priority date, the sequences represented by GenBank Accession Nos AE00159, AE000350, and J01713 are readily ascertainable and definite. As such, the metes and bounds of the claimed subject matter is clear, and Applicant respectfully requests that the Office withdraw this 35 U.S.C. §112, second paragraph rejection.

IV. Rejections Under 35 U.S.C. §112, First Paragraph

The Office rejects claims 50-52 and 59-61 under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the written description requirement. Office Action at 3. Specifically, the Office asserts:

The recitation of tRNA sequences comprising sequences of Genbank Accession Nos. in claims 50-52 and 59-61 is an attempt to incorporate essential, claimed subject matter by reference to prior art documents (i.e. the Genbank entries). A review of the disclosure as filed does not reveal these DNA sequences, thus there is no evidence applicants had possession of these specific DNA sequences. The incorporation of essential material in the specification by reference to an unpublished U.S. application, foreign application or patent, or to a publication is improper. See MPEP §608.01(p) (I). Applicant is required to amend the disclosure to include the material incorporated by reference, if the material is relied upon to overcome any objection, rejection, or other requirement imposed by the Office.

Id. at 4. Applicant respectfully traverses this rejection.

As noted above, there is no per se rule that written description requirement for nucleic acids can only be satisfied by a recitation of the actual nucleotide sequences in the specification. In fact, the Federal Circuit has held that requiring an Applicant to recite known DNA structures is at odds with the goals of the written description requirement:

Indeed, a requirement that patentees recite known DNA structures, if one existed, would serve no goal of the written description requirement. It would neither enforce the quid pro quo between the patentee and the public by forcing the disclosure of new information, nor would it be necessary to demonstrate to a person of ordinary skill in the art that the patentee was in possession of the claimed invention. As we stated in *Capon*, “[t]he ‘written description’ requirement states that the patentee must describe the invention; it does not state that every invention must be described in the same way. As each field evolves, the balance also evolves between what is known and what is added by each inventive contribution.” *Id.* at 1358. Indeed, the forced recitation of known sequences in patent disclosures would only add unnecessary bulk to the specification.

Falko-Gunter Falkner, 448 F.3d at 1368.

The sequences represented by SEQ ID NOs 14-16 were known and accessible from GenBank and other references as of Applicant's priority date. Applicant refers to these known sequences in the specification using the shorthand Accession numbers: AE00159, AE000350, and J01713. The Federal Circuit has held that, as in this case, where "accessible literature sources clearly provided, as of the relevant date, genes and their nucleotide sequences . . . , satisfaction of the written description requirement does not require either the recitation or incorporation by reference (where permitted) of such genes and sequences." *Id.*; *see also, Enzo Biochem, Inc. v. Gen-Probe Inc.*, 3323 F.3d 956, 966 (Fed. Cir. 2002) ("We therefore agree with Enzo that reference in the specification to deposits of nucleotide sequences describe those sequences sufficiently to the public for purposes of meeting the written description requirement."). Accordingly, Applicant is not required to recite the actual nucleotide sequences of these known nucleic acid molecules in the application; nor is Applicant required to incorporate them by reference. Applicant's reference in the application to the Accession numbers of these known and deposited sequences adequately satisfies the written description requirement. *See Falko-Gunter Falkner*, 448 F.3d at 1368. Thus, Applicant respectfully requests the Office to withdraw this written description rejection.

V. Rejections Under 35 U.S.C. §101

The Office rejects claims 54 and 58 under 35 U.S.C. §101 alleging that the subject matter is directed to non-statutory subject matter. Office Action at 10. The Office asserts that the "nucleic acid is not recited as purified or isolated, and thus reads on the *E. coli* genome, a product of nature." *Id.* Applicant has amended claim 54 to recite an "isolated" nucleic acid. Claims 55-61 depend directly or indirectly from claim 54. Accordingly, Applicant respectfully requests the Office to withdraw this rejection.

VI. Rejections Under 35 U.S.C. §103

A. *Del Tito* in Combination with *Nakamura, Zhang, Saier, Kawakami, Clouthier, and Sprinzl* Do Not Render Claims 45-48, 53-56, and 58 Obvious

The Office rejects claims 45-48, 53-56, and 58 under 35 U.S.C. §103(a) as allegedly obvious over *Del Tito* et al. (“*Del Tito*”) in view of *Nakamura* et al. (“*Nakamura*”), *Zhang* et al. (“*Zhang*”), *Saier*, *Kawakami* et al. (“*Kawakami*”), *Clouthier* et al. (“*Clouthier*”), and *Sprinzl* et al. (“*Sprinzl*”). Office Action at 5-9. Applicant respectfully traverses this rejection.

To establish a *prima facie* case of obviousness, the prior art reference (or references when combined) must teach or suggest all the claim limitations. *See* M.P.E.P. § 2142. Applicant submits that the combined teachings of the cited references do not teach all of the elements of the rejected claims.

Claims 45 and 54¹ recite “sequences encoding *E. coli* argU, ileY, and leuW tRNAs.” The Office acknowledges that *Del Tito* fails to teach the use of a vector comprising an array of the three tRNAs: argU, ileY, and leuW. Office Action at 6. However, the Office asserts:

It would have been obvious to one of ordinary skill in the art at the time of the invention to modify the vector construct taught by *Del Tito* et al for compensating for the presence of rarely used codons present in the gene encoding a protein of interest by interchanging and/or **adding different tRNA genes** corresponding to other rarely used codons in a given cell type, because *Del Tito* et al teach that it is within the skill of the art to carefully scrutinize the coding sequence of a protein, identify rarely used codons and compensate for the presence of such rarely codons by supplying in trans the RNA corresponding to the identified rarely used codons from a vector expressing different tRNA genes, and because the rarely used codons and corresponding genes were widely known in the art (i.e. the teachings of *Nakamura* et al, *Zhang* et al, *Saier*, *Sprinzl* et al, *Kawakami* et al and *Clouthier* et al). One would have been motivated to do so in order to meet the particular rare-codon requirements of a gene encoding a desired protein in combination

¹ The remaining claims under rejection depend directly or indirectly from independent claims 45 and 54.

with a given cell type, and thus receive the expected benefit of increasing its expression in the given cell type, as taught by Del Tito et al.

Office Action at 7-8; emphasis added. Thus, the Office asserts that it would have been obvious to one of skill in the art to add different tRNA genes to the vectors of *Del Tito*. Applicant respectfully disagrees.

The *ileX* gene encodes a tRNA that recognizes the AUA codon, a codon that is rarely used in *E. coli*. To enhance the expression of heterologous proteins in *E. coli*, *Del Tito* teaches coexpressing the heterologous protein and the *ileX* gene. *Del Tito* inserted the *ileX* DNA into three pBR322-compatible vectors, one of which (pRI952) was a pACYC184 derivative containing a second tRNA gene, *argU*. *Del Tito* does not teach a vector or nucleic acid containing three tRNA genes. Moreover, *Del Tito* actually teaches away from adding a third tRNA gene to vectors for expressing heterologous proteins.

A prior art reference must be considered in its entirety, i.e., as a whole, including portions that would lead away from the claimed invention. *W.L. Gore & Assoc., Inc. v. Garlock, Inc.*, 721 F.2d 1540, 22 USPQ 303 (Fed. Cir. 1983). See M.P.E.P. § 2141.02. *Del Tito* observed less heterologous protein expression when using the pRI952 vector containing two tRNA genes (*ileX* and *argU*). See *De Tito*, page 7089, second column (Table 1). In addition, *Del Tito* notes that overexpression of tRNA genes is deleterious to the cell. *Id.* at 7090, second column, second paragraph. This is consistent with the specification, which states that “[o]verexpression of tRNA genes can be deleterious to the host cell, however. Rojiani et al., Proc. Nat. Acad. Sci. U.S.A. 87:1511-1515 (1990); Sharp et al., Nucleic Acids Res. 14:7737-7749 (1986).” Specification, page 3, lines 12-14. Thus, taken together and considered as a whole, *Del Tito* in combination with other art, like *Rojiani* and *Sharp*, teaches away from using three or more tRNAs in a host

cell to enhance heterologous gene expression. As indicated in *Del Tito*, expression of two tRNAs reduces heterologous protein expression as compared to vectors containing a single tRNA gene. Furthermore, *Del Tito* and other art references teach that overexpression of tRNA genes is deleterious to host cells. Thus, one of skill in the art would not have been motivated to increase the number and amount of tRNA gene expression because he would have expected such an increase to have a deleterious effect on the host cell.

Accordingly, the cited references fail to teach or suggest all of the elements of the claimed invention. For at least this reason, Applicant submits that the Office has not established a *prima facie* case of obviousness.

Furthermore, determining whether an invention is obvious from the prior art can require more than merely analyzing the differences between the prior art and the claimed invention. The Supreme Court has instructed that courts may also evaluate “secondary considerations” of obviousness, *i.e.*, other objective factors that may show that an invention was not obvious from the prior art, even if the differences between the prior art and the claimed invention seem slight. *Graham v. John Deere Co. of Kansas City*, 383 U.S. 1, 17-18, 86 S. Ct. 684, 694, 15 L. Ed. 2d 545, 148 USPQ 459, 467 (1966) (“Such secondary considerations as commercial success, long felt but unsolved needs, failure of others, etc., might be utilized to give light to the circumstances surrounding the origin of the subject matter sought to be patented. As indicia of obviousness or nonobviousness, these inquiries may have relevancy.” Indeed, “[i]t is the secondary considerations that are often the most probative and determinative of the ultimate conclusion of obviousness or nonobviousness.” *Pro-Mold and Tool Co. v. Great Lakes Plastics, Inc.*, 75 F.3d 1568, 1573, 37 USPQ2d 1626, 1630 (Fed. Cir. 1996) (reversing summary judgment of obviousness because district court failed to consider patentee’s commercial success).

Here, the Office must consider the evidence of commercial success submitted in parent Application No. 09/492,590 (*see* Attachments D and E), evidence providing an objective indication of non-obviousness. Specifically, the Rule 132 Declarations report the significant sales figures of competent cells (BL21-CodonPlus™ RIL (Catalog # 230240); BL21-CodonPlus™ (DE3)-RIL (Catalog # 230245); and BL21-CodonPlus™ (DE3)-RIL-X (Catalog # 230265); the “RIL products”) comprising a vector or nucleic acid having sequences encoding *E. coli* argU, ileY, and leuW tRNAs, as recited in the pending claims. As explained in the Rule 132 Declaration, the commercial success of the RIL products is due to the presence of three tRNA genes (i.e., argU, ileY, and leuW) encoding rarely used codons (*see* Attachment D at page 3, ¶2), thereby establishing a nexus between the commercial success and the claimed invention. *J.T. Eaton & Co. v. Atlantic Paste & Glue Co.*, 106 F.3d 1563, 1571, 41 USPQ2d 1641, 1647 (Fed. Cir. 1997) (“When a patentee can demonstrate commercial success, usually shown by significant sales in a relevant market, and that the successful product is the invention disclosed and claimed in the patent, it is presumed that the commercial success is due to the patented invention.”)

Accordingly, for the reasons set forth above, Applicant requests that the Office reconsider and withdraw the 35 U.S.C. § 103 rejection of claims 45-48, 53-56, and 58 based on *Del Tito* in combination with *Nakamura*, *Zhang*, *Saier*, *Kawakami*, *Clouthier*, and *Sprinzl*.

B. *Del Tito* in Combination with *Nakamura*, *Zhang*, *Saier*, *Kawakami*, *Clouthier*, *Sprinzl*, and Further in View of *Skerra*, Do Not Render Claims 49 and 57 Obvious

The Office rejects claims 49 and 57 under 35 U.S.C. §103(a) as allegedly obvious over *Del Tito*, *Nakamura*, *Zhang*, *Saier*, *Kawakami*, *Clouthier*, and *Sprinzl* as applied to claims 45-48, 53-56, and 58 and further in view of U.S. Patent No. 5,849,576 to Skerra et al. (“*Skerra*”). Office Action at 9-10. Applicant respectfully traverses this rejection.

Applicant submits that the combined teachings of the cited references do not teach all of the elements of the rejected claim. As noted above, neither *Del Tito*, *Nakamura*, *Zhang*, *Saier*, *Kawakami*, *Clouthier*, nor *Sprinzel* teaches or suggests a nucleic acid or vector comprising sequences encoding *E. coli* argU, ileY, and leuW tRNAs. *Skerra* fails to remedy the deficiencies of *Del Tito*, *Nakamura*, *Zhang*, *Saier*, *Kawakami*, *Clouthier*, and *Sprinzel*. Accordingly, the cited references fail to teach or suggest all of the elements of the claimed invention. For at least this reason, Applicant requests that the Office reconsider and withdraw the 35 U.S.C. § 103 rejection of claims 49 and 57 based on *Del Tito*, *Nakamura*, *Zhang*, *Saier*, *Kawakami*, *Clouthier*, and *Sprinzel* in combination with *Skerra*.

VII. Conclusion

In view of the foregoing Amendment and Remarks, Applicant submits that this application is in condition for allowance. Applicant therefore requests entry of this Amendment, the Examiner's reconsideration and reexamination of the application, and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this paper and charge any additional required fees to Deposit Account No. 50-3740.

Respectfully submitted,
Carsten-Peter CARSTENS

Date: 27 December 2007

By: / Timothy B. Donaldson/
Timothy B. Donaldson
Reg. No. 43,592

LATIMER, MAYBERRY & MATTHEWS IP LAW, LLP
13873 Park Center Road
Suite 122
Herndon, VA 20171

Tel. 703-463-3073
Fax. 703-463-3071

Attachments:

GenBank Accession No. AE000159 printout from NCBI website (Attachment A)

GenBank Accession No. AE000350 printout from NCBI website (Attachment B)

GenBank Accession No. J01713 printout from NCBI website (Attachment C)

Copy of Rule 132 Declaration of Mary Buchanan from parent Application No. 09/492,590
dated 8 February 2001 (Attachment D)

Copy of Rule 132 Declaration of Mary Buchanan from parent Application No. 09/492,590
dated 8 November 2001 (Attachment E)

ATTACHMENT A



My NCBI

[\[Sign In\]](#) [\[Register\]](#)

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Books

Search for

Limits

Preview/Index

History

Clipboard

Details

Display Show Send to Hide: ☐ sequence ☐ all but gene, CDS and mRNA featuresRange: from to ☐ Reverse complemented strand Features: ☐ 1: AE000159. Reports ...[gi:1786739] The record has been replaced by U00096[Comment](#) [Features](#) [Sequence](#)

LOCUS AE000159 10133 bp DNA linear BCT 01-DEC-2000

DEFINITION Escherichia coli K12 MG1655 section 49 of 400 of the complete genome.

ACCESSION AE000159 U00096

VERSION AE000159.1 GI:1786739

KEYWORDS .

SOURCE Escherichia coli K12

ORGANISM Escherichia coli K12
Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales; Enterobacteriaceae; Escherichia.

REFERENCE 1 (bases 1 to 10133)

AUTHORS Blattner, F.R., Plunkett, G. III, Bloch, C.A., Perna, N.T., Burland, V., Riley, M., Collado-Vides, J., Glasner, J.D., Rode, C.K., Mayhew, G.F., Gregor, J., Davis, N.W., Kirkpatrick, H.A., Goeden, M.A., Rose, D.J., Mau, B. and Shao, Y.

TITLE The complete genome sequence of Escherichia coli K-12

JOURNAL Science 277 (5331), 1453-1474 (1997)

PUBMED 9278503

REFERENCE 2 (bases 1 to 10133)

AUTHORS Blattner, F.R.

TITLE Direct Submission

JOURNAL Submitted (16-JAN-1997) Guy Plunkett III, Laboratory of Genetics, University of Wisconsin, 445 Henry Mall, Madison, WI 53706, USA. Email: ecoli@genetics.wisc.edu Phone: 608-262-2534 Fax: 608-263-7459

REFERENCE 3 (bases 1 to 10133)

AUTHORS Blattner, F.R.

TITLE Direct Submission

JOURNAL Submitted (02-SEP-1997) Guy Plunkett III, Laboratory of Genetics, University of Wisconsin, 445 Henry Mall, Madison, WI 53706, USA. Email: ecoli@genetics.wisc.edu Phone: 608-262-2534 Fax: 608-263-7459

REFERENCE 4 (bases 1 to 10133)

AUTHORS Plunkett, G. III.

TITLE Direct Submission

JOURNAL Submitted (13-OCT-1998) Laboratory of Genetics, University of Wisconsin, 445 Henry Mall, Madison, WI 53706, USA

COMMENT [WARNING] On Jun 21, 2004 this sequence was replaced by [gi:48994873](#).
This sequence was determined by the E. coli Genome Project at the University of Wisconsin-Madison (Frederick R. Blattner, director). Supported by NIH grants HG00301 and HG01428 (from the Human Genome Project and NCHGR). The entire sequence was independently determined from E. coli K12 strain MG1655. Predicted open reading frames were determined using GeneMark software, kindly supplied by Mark Borodovsky, Georgia Institute of Technology, Atlanta, GA, 30332 [e-mail: mark@ambergatech.edu]. Open reading frames that have been correlated with genetic loci are being annotated with CG Site Nos., unique ID nos. for the genes in the E. coli Genetic Stock Center (CGSC) database at Yale University, kindly supplied by Mary Berlyn. A public version of the database is accessible (<http://cgsc.biology.yale.edu>). Annotation of the genome is an ongoing task whose goal is to make the genome sequence more useful by correlating it with other data. Comments to the authors are appreciated. Updated information will be available at the E. coli Genome Project's World Wide Web site (<http://www.genetics.wisc.edu>). *** The E. coli K12 sequence and its annotations are periodically updated; this is version M54. No sequence changes. Annotation updates: updated gene identifications

and products; all new functional assignments courtesy of Monica Riley; added promoters, protein binding sites, and repeated sequences described in reference 1. The unique numeric identifiers beginning with a lowercase 'b' assigned to each gene (protein- or RNA-encoding) are now designated as gene synonyms instead of labels. This should allow them to be searched for in Entrez as gene names.

FEATURES	Location/Qualifiers
source	1..10133 /organism="Escherichia coli K12" /mol_type="genomic DNA" /strain="K12" /sub_strain="MG1655" /db_xref="taxon:83333"
<u>promoter</u>	complement(<1..20) /note="factor Sigma70; predicted +1 start at 555785"
<u>promoter</u>	complement(9..37) /note="factor Sigma70; predicted +1 start at 555802"
<u>gene</u>	complement(84..317) /gene="ybcJ" /note="synonym: b0528"
<u>CDS</u>	complement(84..317) /gene="ybcJ" /function="orf; Unknown" /note="f77; 98 pct identical to YBCJ_ECOLI SW: P45571 but has 7 additional N-ter residues" /codon_start=1 /transl_table=11 /product="orf, hypothetical protein" /protein_id="AAC73630.1" /db_xref="GI:1786740" /translation="MIHRMSNMATFSLGKHPHVELCDLLKLEGWSESGAQAKIAIAEGQVKVDGAVETRKRCIVAGQTVSFAGHSVQVVA"
<u>gene</u>	complement(298..1164) /gene="fold" /note="synonym: b0529"
<u>CDS</u>	complement(298..1164) /gene="fold" /EC_number="1.5.1.5" /function="enzyme; Biosynthesis of cofactors, carriers: Folic acid" /note="f288; 99 pct identical to FOLD_ECOLI SW: P24186" /codon_start=1 /transl_table=11 /product="5,10-methylene-tetrahydrofolate dehydrogenase; 5,10-methylene-tetrahydrofolate cyclohydrolase" /protein_id="AAC73631.1" /db_xref="GI:1786741" /translation="MAAKIIDGKTIAQQVRSEVAQKVQARIAAGLRAPGLAVVLVGSN PASQIVASKRKACEEVGFVSRSYDLPETTSEAELELIDTLNADNTIDGILVQLPLP AGIDNVKVLRIHPDKVDGDFHPYNVGRLCQAPRLRPCTPRGIVTLLERYNIDTFGL NAVVIGASNIVGRPMSMELLLAGCTTTVTHRFTKNLRHHVENADLLIVAVGKPGFIPG DWIKEGAIVIDVGINRLENGKVVDVVFEDAAKRASYITVPVGGVGPMVTATLIENTL QACVEYHDPQDE"
<u>promoter</u>	complement(322..351) /gene="fold" /note="factor Sigma70; predicted +1 start at 556115"
<u>promoter</u>	complement(397..428) /gene="fold" /note="factor Sigma70; predicted +1 start at 556190"
<u>promoter</u>	complement(401..429) /gene="fold" /note="factor Sigma32; predicted +1 start at 556194"
<u>promoter</u>	complement(454..482) /gene="fold" /note="factor Sigma70; predicted +1 start at 556247"
<u>promoter</u>	1553..1581 /note="factor Sigma70; predicted +1 start at 557388"
<u>gene</u>	1602..2177 /gene="sfmA" /note="synonym: b0530"
<u>CDS</u>	1602..2177 /gene="sfmA" /function="putative structure; Not classified" /note="o191; This 191 aa ORF is 66 pct identical (5 gaps) to 180 residues of an approx. 192 aa protein FM1A_SALTY SW: P37921" /codon_start=1

/transl_table=11
/product="putative fimbrial-like protein"
/protein_id="AAC73632.1"
/db_xref="GI:1786742"
/translation="MESINEIEGIYMKLRFISSALAAALFAATGSYAAVVDGGTIHFE
GELVNAACSVNTDSADQVVTLGQYRTDIFNAVGNLSALIPFTIQLNDCDPVVAANA
AFSGQADAINDLLAIASSTNTTATGVGIEILDNTSAILKPDGNSFSTNQNLIPGTN
VLHFSARYKGTGSASAGQANADATFIMRYE"
promoter 2325..2354
/note="factor Sigma70; predicted +1 start at 558161"
gene 2397..3089
/gene="sfmC"
/note="synonym: b0531"
CDS 2397..3089
/gene="sfmC"
/function="putative factor; Not classified"
/note="o230 was o215; This 230 aa ORF is 62 pct identical
(0 gaps) to an approx. 232 aa protein FIMC_SALTY SW:
P37923"
/codon_start=1
/transl_table=11
/product="putative chaperone"
/protein_id="AAC73633.1"
/db_xref="GI:1786743"
/translation="MMTKIKLLMLIIFYLIISASAHAGGIALGATRIIYPADAKQTA
VWIRNSHTNERFLVNSWIENSSGVKEKSFITPPLFVSEPKSENTLRRIYTGPPLAAD
RESLEFWMNVKTIPSVDKNALNGRNVQLAILSRMKFLRPIQLQELPAEAPDTLKFSR
SGNYINVHNPSFFYVTLVNLQVGSQKLGNAAPRVNSQIPLPSGVQKLFQTVNDY
GSVTPVREVNLN"
gene 3120..5723
/gene="sfmD"
/note="synonym: b0532"
CDS 3120..5723
/gene="sfmD"
/function="putative membrane; Not classified"
/note="o867; residues 25-568 are 69 pct identical (2 gaps)
to aa 26-569 from FIMD_SALTY SW: P37924 (870 aa)"
/codon_start=1
/transl_table=11
/product="putative outer membrane protein, export
function"
/protein_id="AAC73634.1"
/db_xref="GI:1786744"
/translation="MKIPTTTDIPQRYTWCLAGICYSSLAILPSFLSYAESYFNPAPFL
LENGTSVADLSRFRGNHQPAGVYRVDLWRNDEFIGSQDIVFESTENTGDKSGGLMP
CFNQVLLERIGLNSSAFPELAQQQNNKCINLLKAVPDATINFDFAAMRLNITIPQIAL
LSSAHGYIPPEEWDEGIPALLLNYNFTGNRGNNGDSYFFSELSGINIGPWRLRNGSW
NYFRNGYHSEQWNNIGTWVQRAIPLKSELVMGDGNTGSDIFDGVGFRGVRLYSSDN
MYPDSQQGFAPTVRGIARTAAQLTIRQNGFIIYQSYVSPGAFEITDLHPTSSNGDLV
TIDERDGNQQNYTIPYSTVPILQREGRFKFDLTAGDFRSNGNSQQSSPFFQGTALGGL
PQEFYAGGTQLSANYTAFLLGLGRNLGNWGAVALDVTHARSQADASRHEGDSIRFL
YAKSMNTFGTNFQLMGYRYSTQGFYTLDDVAYRRMEGYEYDYGDEHRDEPIIVNYHNL
RFSRKDRLQLNVSQSLNDFGSLYISGTHQKYWNTSDSDTWYQVGYTSSWVGISYLSF
SWNESVGIPDNERIVGLNVSVFENVLTKRRTRENALDRAYASFANRNSNGQNSWLA
GVGGTLLLEGHNSYHVSQGDTSNNGYTGSATANWQAAYGTGGGYNDRDQHDVNWQL
SGGVVGHENGITLSQPLGDTNVLIKAPGAGGVRIENQTGILTDRGYAVMLYATVYRY
NRIALDNTMGNSIDVEKNISSVPTQGALVRANFDTRIGVRALITVTQGGKPVPFPS
LVRENSTGITSVMVGDDGQVYLSGAPLSGELLVQWGDGANSRCIAHYVLPKQSLQQA
VTVISAVCTHPSG"
gene 5765..6742
/gene="sfmH"
/note="synonym: b0533"
CDS 5765..6742
/gene="sfmH"
/function="phenotype; Not classified"
/note="o325; 69 pct identical to FIMH_SALTY SW: P37925
(335aa)"
/codon_start=1
/transl_table=11
/product="involved in fimbrial assembly"
/protein_id="AAC73635.1"
/db_xref="GI:1786745"
/translation="MACLCLANISWATVCANSTGVAEDEHYDLSNIFNSTNNQPGQIV
VLPEKSGWVGVSACPPGTLVNYTYRSYVTNFIVQETIDNYKYMQLHDYLLGAMSLVD
SVMIDIQFPFQNYIRMGTDPNVSNLPPFGVMDSRILFRLKVIRPFINMVEIPRQVMFTV
YVTSTPYDPLVTPVYTISFGGRVEVPQNCNELNAGQIVEFDGFDIGASLFSAAAGPNRP
AGVMPQTKSIYVKTNVAAQAYLTMRLEASAVSGQAMVSDNQDLGFIVADQNDTPITP
NDLNSVIPRFLDAAAAANVTLRAWPIISITGQKPTGPFPSALGYLRVDYQ"

gene 6753..7268
/gene="sfmF"
/note="synonym: b0534"

CDS 6753..7268
/gene="sfmF"
/function="putative structure; Not classified"
/note="ol171; formerly designated ybcG; 57 pct identical (1 gap) to FIMF_SALTY SW: P37926 (172 aa)"
/codon_start=1
/transl_table=11
/product="putative fimbrial-like protein"
/protein_id="AAC73636.1"
/db_xref="GI:1786746"
/translation="MRRVLFSCFCGLLWSSSGWAVDPLGTININLHGNVVDVFSCTVNT
ADIDKTVDLGRWPTTQLLNAGDTTALVPFSLRLEGCPGGSVALFTGT PASDTNLLAL
DDPAMAQTVAIELRNSDRSRLALGEASPTEEVDANGNVTLNFFANYRALASGVRPGVA
KADAIFMINYN"

gene complement(7271..7903)
/gene="fimZ"
/note="synonym: b0535"

CDS complement(7271..7903)
/gene="fimZ"
/function="putative regulator; Surface structures"
/note="f210; 100 pct identical to FIMZ_ECOLI SW: P21502"
/codon_start=1
/transl_table=11
/product="fimbrial Z protein; probable signal transducer"
/protein_id="AAC73637.1"
/db_xref="GI:1786747"
/translation="MKPTSVIIMDTHPIIRMSIEVLLQKNSLQIVLKTDDYRITIDY
LRTRPVDLIIMDIDLPGTDGFTFLKRIKQIQSTVKVFLSSKSECFYAGRAIQAGANG
FVSKCNDQNDIFHAVQMILSGYTFPPSETLNYIKSNKCSNNSVTVLSNREVTILRY
LVSGLSNKEIADKLLSNKTVSAHKSNIYGKLGHSIVELIDYAKLYELI"

promoter complement(7965..7991)
/note="factor Sigma70; predicted +1 start at 563758"

promoter complement(8040..8069)
/note="factor Sigma70; predicted +1 start at 563833"

gene 8146..8222
/gene="argU"
/note="synonym: b0536"

tRNA 8146..8222
/gene="argU"
/product="tRNA-Arg"
/note="anticodon: UCU; CG Site No. 17755; alternate gene names dnaY, pin"
/function="RNA; tRNA"

gene complement(8238..9401)
/gene="intD"
/note="synonym: b0537"

CDS complement(8238..9401)
/gene="intD"
/function="IS, phage, Tn; Phage-related functions and prophages"
/note="f387; 100 pct identical to INTD_ECOLI SW: P24218"
/codon_start=1
/transl_table=11
/product="prophage DLP12 integrase"
/protein_id="AAC73638.1"
/db_xref="GI:1786748"
/translation="MSLFRRNEIWYASYSLPGGKRIKESLGTKDKRQAQELHDKRKAEL
LWRVEKLGDLPDVTFEEACLRWLEEKADKKS LDSKSRIEFWLEHFEGIRLKDISEAK
IYSAVSRMHNRTKEIWKQKVQAAIRKKGKELPVYEPKPVSTQTKAKHLAMIKAILRAA
ERDWKWLEKAPVIKIPAVRNKRVRWLEKEEAKRLIDECPEPLKSVVKFALATGLRKSN
IINLEWQQIDMQRRVAWVNPEESKSNRAIGVALNDTACKVLRDQIGKHHKWVVFHTKA
AKRADGTSTPAVRKMRIDSKTSWLSACRRAGIEDFRFHDRLRHTWASWLIQSGVPLSVL
QEMGGWESIEMVRRYAH LAPNHLTEHARKIDDIFGDNVPMNSHSEIMEDIKKA"

promoter 9228..9257
/note="factor Sigma70; predicted +1 start at 565064"

promoter 9308..9336
/note="factor Sigma70; predicted +1 start at 565143"

promoter 9341..9373
/note="factor Sigma70; predicted +1 start at 565180"

gene 9395..9955
/gene="b0538"

CDS 9395..9955
/gene="b0538"
/function="putative regulator; Not classified"
/note="ol186; This 186 aa ORF is 29 pct identical (4 gaps)

to 57 residues of an approx. 328 aa protein CRJA_TRICY SW:
Q03442"
/codon_start=1
/transl_table=11
/product="putative sensory transduction regulator"
/protein_id="AAC73639.1"
/db_xref="GI:1786749"
/translation="MTFSFLCYAITRAHLDSMQRRLLKRRNAGLPCCEVPGYYREDASS
PLLPHYKTNFSQCLVHFFDELRRHLVKTRHVLFIPLNHDIMQAFTHARVIVGKVP
FSRHPHAVLHLGHVSRFYCLETTEPEFHEIPGGTSIAGSVACIRMQSLIRGNRTRITG
WLPTCTRTCGPMRWLTRNYGARLPMN"
complement(9443..9471)
/note="factor Sigma70; predicted +1 start at 565236"
gene complement(9521..9784)
/gene="b0539"
CDS complement(9521..9784)
/gene="b0539"
/function="putative enzyme; Not classified"
/note="f87; This 87 aa ORF is 96 pct identical to
87residues of a 226 aa protein EXO_LAMBD SW: P03697 but
contains -139 additional N-ter aa"
/codon_start=1
/transl_table=11
/product="putative exonuclease (EC 3.1.11.3) similar to
lambda"
/protein_id="AAC73640.1"
/db_xref="GI:1786750"
/translation="MKFRLGGFEAIKSAYMAQVOYSMWVTRKDAWYFANYDPRMKREG
LHYVVIERNKYMASFDEMVEFIEKMDEALAEIGFVFGEQWR"
promoter complement(9938..9965)
/note="factor Sigma70; predicted +1 start at 565731"
ORIGIN
1 atgctatcag catgcatgaa cggggcgtag agggcaaaag tctgaaaaga gaaccggcct
61 gttgatacag gccgggaaaag ggaacaggca acaacctgta cgctgtgacc tgcaaaactc
121 actgtctgac cggcgacgat tttgcagcgt ttgcgcgttt caaccgcacc gtcgactttc
181 acctggcctt cggcaatcgc gattttcgcc tgcgcgcgcg tttcgcctcc gccctccagt
241 ttcagcaagt cgcacagctc aacgtgcgga tgtttaccta aagaaaatgt cgccatgtta
301 ctcatcctgt ggaatcatgat attcaacgca cgctgttagc gtgttttcaa tcagcgtggc
361 aaccgtcatc gggccaacgc cgccgggaac aggcgtaatg tatgaggcgc gtttagccgc
421 gtcttcaaac acgacgtcgc ccacaacttt gccattttcc agacggttga tgccgacatc
481 aatcacaatt gcgccttctt tgatccagtc accgggaata aagcctggct tgccaacggc
541 aacgatcaat agatcggcat tttctacgtg atgacgcaga tttttagtga agcgtgtgag
601 cactgtagtgt gtgcaacctg ccagcagcag ttccatgctc atcggggcgc caacgatatt
661 cgatgcgcca atcaccacgc cgttgaggcc gaaggtatca atgttgtaac gctcaagcag
721 cgtgacgata ccgcgcgggg tgcagggacg cagacgcggc gcgcgctggc acagacgacc
781 gacgttgtaa ggatggaaaac cgtccacgctc tttgtccgga tgaatacgtt ccagcacttt
841 gacgttatca ataccgcgcg gtaacgcgag ttgaaccaga atgccatcga tgggtgtgtc
901 ggcattcagc gtatcgataa gctccagcag ctccgcttcg ctgggtggtt ccgggagggtc
961 ataagagcgg gagacgaacc cgacttcttc acaagccttg cgtttgcttg cgacataaat
1021 ttgcgatgca gggttactac ccaccagcac aacggccagt cctgggtccc gcagtcgggc
1081 tgcaatacgc gcctgaactt tttgagcaac ttcagagcgc acctgctgcg caatcgtttt
1141 accgtcaata atctttgctg ccatacagaga gaggattcca tctgttacgt agatcgaagg
1201 ggaatgcgct attttgtcag aagcggggcg cgctgtcagg tttcgtttca gatttatcgc
1261 gtgaagcgac ctcttgcgaa ggtgaggcgc accgtcgctg agactgaaag cttcatTTTT
1321 cgtccatgat ggcgttgtaa atctggaact gatttatTTC cttgtctaag gattaagata
1381 atttaagaaa tacctgacaa tataaaaaga attttcagcc tggtaatTTA ccgcttcagg
1441 tcttatTTT tgttgaaatat attttgcgcg gaagtattca tctaaccggg ctctctattt
1501 tttagaatag agtgcatatt ttcaattaa acattcttag aggataaaaa ggaatttact
1561 actatcagtg tcttaataaa agtaatcggg tatatacgga tgtggagtcg ataaatgaga
1621 ttgaaggaat atatatgaaa ttaagattta tttcgtctgc gctggctgcc gcactattcg
1681 ccgctacggg tagttatgct gccgttgtag atggcggtac aattcacttt gaaggcgaac
1741 tgggtgaatgc tgccgtttca gtgaatactg actcggcaga ccaggttgct acactcggtc
1801 aatatcgtac cgatatTTTC aatgctgttg gtaatacctc tgcattaatt ccattcacca
1861 ttcagttgaa cgactgcgat cctgttggtg ccgctaagtc tgccgttgca ttttctggtc
1921 aggcgtgatgc aatcaatgat aatttatTGG ccattgcac cagtaccaat acaacaacag
1981 caacgggtgt cggtattgaa atacttgata atacatccgc aattctcaa cctgatggga
2041 atagcttctc aaccaaccag aacttgatcc ccgggaccaa cgttcttcat ttttctgcac
2101 gttataaagg caccggtaca agtgcatcag cagggcaagc aaatgctgac gcgactttta
2161 ttatgagata tgaataatca aaaccacggt gttttgaatt atatatcag tcttataaca
2221 aagtaatgta ccggttgctc gaagcgtgat ggtggcaatg taaatcgaaa tcatgttcac
2281 tttgtatcat gccgctttat taaatgaaa ggggaatgat tgttgtaaga aaccaaagca
2341 atcatttctt tatattcctt atttttgccg tcaggaatac acaaggcgta ttaactatga
2401 tgactaaaat aaagttattg atgctcatta tattttattt aatcatttgc gccagcgccc
2461 atgctgccgg agggatcgca ttaggtgcca cgcgatttat ttatcccgtg gatgctaaac
2521 agactcgggt atggattaga aatagccata ccaatgagcg ctttctggtc aattcgtgga
2581 ttgaaaacag cagcgggtga aaagaaaagt cattcatcat tacaccgcca ctgtttgtta
2641 gtgaacccaa aagcgaaaat actttgcgta ttatttacac cgggtccaccg ctggcagcag
2701 atcgtgagtc tctgttctgg atgaatgta agacgatccc ttcggtagat aaaaatgcat

```
2761 tgaacggcag gaatgtttt caactggcga ttttatcgcg catgaaatta tttctccgtc
2821 caattcaatt acaagaatta cccgcagaag cgccggacac actcaagttt tcgcgatccg
2881 gtaactatat caatgttcat aatccatcac ctttttatgt caccctggtt aacttacaag
2941 tggggcagcca aaagtgtggg aatgctatgg ctgcaccag agttaattca caaattccct
3001 taccctcagg agtgcaggga aagctgaaat ttcagaccgt taatgattat ggttcagtaa
3061 ctccggtcag agaagtgaac ttaactaac cgaatcatct gacaatatca gagctaatta
3121 tgaaaaatacc cactactacg gatattccgc agaggtatag ctgggtgtctg gccggaattt
3181 gttattcatc tcttgccatt ttaccctcct ttttaagcta tgcggaaaag tatttcaacc
3241 cggcattttt attagagaaat ggcacatccg ttgttgattt atcgcgcttt gagagaggta
3301 atcatcaacc tgcgggctgt tatcgggtgg atctctggcg taatgatgag ttcatgtgtt
3361 cgcaggatat cgtatttgaa tcgacaacag aaaatacagg tgataaatca ggtgggttaa
3421 tgccctgttt taaccaggta cttcttgaaac gaattggcct taatagcagt gcatttcccg
3481 agtttagccca gcagcaaaac aataaatgca tcaatttact gaaagctgta cctgatgcca
3541 caattaaatt tgattttgca gcgatgcgcc tgaacatcac tttcctcag atagcgttgt
3601 tgagttagcgc tcacgggtac attccgcctg aagagtggga tgaaggattt cctgctttac
3661 tccatgaatt taatttcacc ggtaacagag gtaatggtaa cgtatgctat ttttttagtg
3721 agctcagcgg gattaatatt ggcccggtgc gtttacgcaa caatggttcc tggaaactatt
3781 ttccgcgaaa tggatatcat tcagaacagt ggaataatat tggcacctgg gtacagcgcg
3841 ccattattcc gctgaaaagt gaactggtaa tgggagacgg caatacagga agtgatattt
3901 tcgatggcgt tggatttcgt ggtgtacggc tttattcttc tgataatatg tatcctgata
3961 gccagcaagg gtttgcccca acggtacgtg ggattggccg tacggcggcc cagctaacga
4021 ttccggcaaaa tggttttatt atctatcaaa gctatgtttc ccccggcgct tttgaaatta
4081 cagatttgca cccgacatct tcaaatggcg atctggacgt caccatcgac gagcgcgatg
4141 gcaatcagca gaattacaca attccgtatt caacagtgcc aattttacaa cgcgaagggc
4201 gtttcaaatt tgacctgacg gcggcgcat ttcgtagcgg taatagtcag caatcatcgc
4261 ctttcttttt tcagggtacg gcactcggcg gtttaccaca ggaatttact gcctacggcg
4321 ggaacgaatt atctgccaat tacaccgcct ttttattagg gctggggcgc aatctcggga
4381 actggggcgc agtgtcgtg gatgtaacgc atgcgcgcag tcagttagcc gacgccagtc
4441 gtcgatgagg ggattctatt cgcttctct atgcgaaatc gatgaacacc ttcggcacca
4501 attttcagtt aatgggttac cgctattcga cacaaggttt tgagcatcgc gatgaaccga
4561 cgtatcgtcg aatggagggg tacgaatatg attacgacgg gccgtaaaga ccgtttgcag ttaaatgttt
4621 taatcgtgaa ttaccacaat ttacgcttta gccgtaaaga ccgtttgcag ttaaatgttt
4681 cacaatcact taatgacttt ggctcgtttt atatttctgg taccatcaa aaatactgga
4741 atacttcgga ttcagatacg tggatcagg tgggtatata cagcagctgg gttggcatca
4801 gttattcgct ctcattttcg tggaatgaat ctgtagggat ccccgataac gaacgtattg
4861 tcggacttaa tgtttcagtg cctttcaatg ttttgaccaa acgtcgtac acccgggaaa
4921 atgcgctcga ccgcgcttat gcctccttta acgccaaccg taacagcaac gggcaaaaa
4981 gctggctggc aggtgtaggt gggaccttac tggaaaggcca caacctgagt tatcacgtaa
5041 gccagggtga tacctcgaat aatgggtaca cgggcagcgc caccgcaaac tggcaggccg
5101 cttacggtac gctggggggc ggggtataact acgaccgcga tcaacatgac gtttaactggc
5161 agctgtctgg cgggtgtgtc gggcatgaaa atggcataac gctgagccag cctttagggg
5221 ataccaatgt tttgattaaa gcgcctggcg caggcgtgtg acgcatgaa aatcaaactg
5281 gcattttaac cgactggcgc ggctatgcgg tgatgtgta tgccaagggt tatcgggtata
5341 accgtatcgc gcttgatacc aatacgtatg ggaattccat cgtatgtgaa aaaaatatta
5401 tgcgcgttgt gccgacgcaa ggccgcttgg ttctgccaac ttttgatacc cgcataggcg
5461 tgaggcgctt cattaccggt acccaggcgc gaaaaccggt gccgtttgga tccactgtac
5521 gggaaaaacag taccggaata accagtatgg tgggtgatga cgggcaagtt tatttaagt
5581 gtgcgccatt gtctggtgaa ttactggttc agtggggaga cggcgcaaac tcacgctgca
5641 ttgcgcacta tgtattgccg aagcaaaagt tacagcaagc cgtcactgtt atttcggcag
5701 tttgcacaca tcctggtcca taaaggaaat tatcaataag ataactgca gattattatt
5761 ggcatgagca tgtttgtgtc tggcaaacat atcctgggct actgtttgtg caaatagtac
5821 tggcgtagca gaagatgaac actatgatct ctcaaatatc ttaatatgca ccaataacca
5881 gccaggcgag attgttgttt taccggaaaa atccggctgg gtaggtgtct cagcaatttg
5941 tccaccgggt acgctggtga attatacata cgtagtatat gtcaccaact ttattgttca
6001 ggaaactatc gataattata aatatatgca attacatgat tatctattag gtgcgatgag
6061 tctggttgat agtgtgatgg atattcagtt cccccgcaa aattatattc ggatgggaac
6121 agatcctaac gtttcgcaaa acccttcatt cgggggtgat gattctcgtt taatatttcg
6181 tttaaaaggtt attcgtccct ttattaacat ggtggagatc cccagacagg tgatgtttac
6241 cgtgtatgtg acatcaacgc cttacgatcc gttggttaca cctgtttata ccattagttt
6301 tgggtggcgg gttgaagtac cgcaaaaact cgaattaaat gccgggcaga ttgttgaatt
6361 tgattttggt gatatcggcg catcgttatt tagtgcggca gggccgggta atcgacctgc
6421 tgggtgtcgt ccgcaaacca agagcattgc ggtcaaatgt acgaatgttg ctgcgcaggc
6481 ttatttaaca atgcgtctgg aagccagtgc cgtttctggt caggcgatgg tgcggacaa
6541 tcaggattta ggttttattg tcgccgatca gaacgatacg ccgatcacgc ctaacgatct
6601 caatagcgtt attcctttcc gtctggatgc agctgcggca gccaatgtca cacttcgcgc
6661 ctggcctatc agtattaccg gtcaaaaaacc gaccgaaggg ccgtttagcg cgctggggta
6721 tttacgcgtc gattatcaat gaggtacgga gaatgagaag agtactcttt agctgtttct
6781 cggggctact gtggagtccc agtggatggg cagttgacct ttaggaaacg attaatatca
6841 atttgacagg taacgttgtt gatttctcct gtaccgtaaa cacagcggat attgataaga
6901 cggtagattt aggcagatgg cctacgacac aactactgaa cgctggcgat accacggcac
6961 tcgtcccttt tagcctcggc ctggagggat gtccctccgg ttcagttgcg attttattta
7021 cgggaacgcc ggcattccg ataccctgc accaacctgc tggctctgga tgatccccga atggcacaaa
7081 ccgtcgcctt cgaattacgt aatagcgatc gctcccggct cgcactgggg gaggcgagcc
7141 cgactgagga agtagatgca aatggcaatg tcacactaaa cttttttgcc aattatcgag
7201 cgtagccagg cgggtgttcg ccagggtgtg cgaaagcgga tgcgatattt atgatcaatt
7261 ataattaaata ttataattaat tcgtataatt tggcgtagtc gataagctct acaattgaat
7321 gcaaacctag cttgccataa atattagatt tatgcgcact aactgtttta ttgctaagta
7381 ataacttatc ggcaatttct ttattagata atccgctaac cagataacgt aatatggtca
```




```
7441 cttcacgatt agatagcaca gtgaccgttg aactattcgt actacattta ttgcttttta
7501 tatagttaag cgtttcgtcg ggaaaaaacg tgtatccgga gaggatcatc tgaacggcat
7561 gaaaaatatc attctgatca ttgcatttac tgacaaaacc gttagcacca gcttgatcg
7621 ctctgccagc ataaaagcat tctgatttcg atgataaaaa taacactttc actgtgctct
7681 ggatttggtt gatccttttc aggaaggtaa aaccgtctgt tccgggcaag tctatatcca
7741 taatgattaa atcaacagga cgggttcgga gataatcgat ggttatgcga taatcatccg
7801 ttttcaggac aatctgcaat tcactgtttt ttgcaaacag aacttcaata gacattctga
7861 tgcaggatg agtatccata atgatcaccc acgttggttt catagttacc agtctcatag
7921 gagcggacaa ttttcggtta ggtcgggaaa ttgtactttg atacatgaaa atacgggttt
7981 tcttgattca gacgcgcagc ggtgtgcgtt tgtttgccgc tatagcgaaa taaatcagaa
8041 aatcagacgc ggtcgttcac ttgttcagca accagatcaa aagccattga ctacgcaagg
8101 gttgaccgta taattcacgc gattacaccg cattgcggta tcaacgcgcc cttagctcag
8161 ttggatagag caacgacctt ctaagtcgtg ggccgcaggt tcgaatcctg cagggcgccg
8221 cattacaatt caatcagtta cgcttctctt atactctcca taatttcaga gtgggacata
8281 tttgggacat tatcaccaaa aatgtcgtct attttcctcg catgctctgt caaatgatta
8341 gtcgcaaggc gagcatacct acgaaccatt tctatggact cccatccgcc catttcctga
8401 agcactgata atgggacgcc tgactgaatc agccagcttg cccaggtgtg tctgaggta
8461 tggaaacgga aatcttcaat tcttcgacga cgacaagctg atagccatga tgtcttgctg
8521 tcgatgcgca tcttcctgac cgcaggcgtt gatgttccat ctgctcgctt agccgccttg
8581 gtatgtacaa acacccattt gtgatgcttg cctatttgat cacgcaacac tttacaggcg
8641 gtatcggtca gcgccacacc aatggcgccg tttgatttgc tctcttctgg attcaccag
8701 gcaactcgtc gctgcatgtc gatttgttgc cattccagat ttatgatgtt cgactttctc
8761 agccagttg ccagcgcaaa cttgacgaca gatttcagtg gttcggggca ctcataata
8821 agcgcttttg ctctctctt ttccagccat ctgactcgct tgtttctgac cgctggtatc
8881 ttgatgacag gcgctttttc cagccacttc cagtcgcgtt ctgcagcacg gagaatggcc
8941 tttatcatgg caagatgctt tgctttgtc tgagttgata ctggctttgg ttcataaaca
9001 gtcagttctt taccttttct gatggcgcc gtttccatat ttctttctgc
9061 tttctgttat gcattctgct tacagcagag taaatctttg cctccgagat atctttaagc
9121 cttataccct caaaatgttc aagccagaac tcaatccggc ttttatctga atcgagagat
9181 tttttatcag ctttttcttc aagccatctt aggcaggcct cttcaaaagt gacatcaggt
9241 aaatccccta gcttttctac tcgcoagagt tctgcttttc gcttgctgtg caactcctga
9301 gcttgccgtt tgtcctttgt gccaaagagt tccttaattc gtttcccgcc cgggagcgaa
9361 tacgaggcat accatatttc atttctgcgg aagagtgaca ttttctttcc tctgttatgc
9421 catcacccgc gctcacctgg acagtatgca gcggagactg aagcgccgca atgcaggctt
9481 gccgtgttgt gaggtacccg gatattatcg tgaggatgcg tcatcgccat tgctcccaa
9541 atacaaaacc aatttcagcc agtgcctcgt ccattttttc gatgaactcc ggcaccatct
9601 cgtcaaaact cgccatgtac ttttcatttc gtcacatcac gacataatgc aggccttcac
9661 gcttcatgcg cgggtccatag ttggcaaatg accaggcatc ttttcgcgtc accacatgc
9721 tgtactgcac ctgggccatg taagccgatt ttattgctc gaaaccaccg agccggaatt
9781 tcatgaaatc ccgggaggta cgagtattgc cggaagcgtg gcctgtatcc ggatgcagag
9841 tcttatccgt ggaaatcgaa cgcgcattac tgggttggtt ccaacttgta ccagaacatg
9901 cgggccaatg cgctggctga cgcggaatta cggcgcaagg ctgccgatga actgacctgt
9961 atgacagcgc gaattaaccg tgggtgagacg atacctgaac cagtaaaaca acttcctgtt
10021 atgggcggta gacctctaaa tcgtgcacag gctctggcga agatcgcaga aattaaagct
10081 aagttcggac tgaaaggagc aagtgtatga cgggcaaaga ggcaattatt cat
```

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Aug 28 2007 16:53:42

ATTACHMENT B



My NCBI

[\[Sign In\]](#) [\[Register\]](#)

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Books

Search **Nucleotide**

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display **GenBank**Show **5**

Send to

Hide: ☐sequence ☐

all but gene, CDS and mRNA features

Range: from **begin**to **end**☐ Reverse complemented strandFeatures: **+****Refresh**☐ **1: AE000350.** Reports ...[\[gi:2367147\]](#) The record has been replaced by [U00096](#)**Comment** **Features** **Sequence**

LOCUS AE000350 10401 bp DNA linear BCT 01-DEC-2000

DEFINITION Escherichia coli K12 MG1655 section 240 of 400 of the complete genome.

ACCESSION AE000350 U00096

VERSION AE000350.1 GI:2367147

KEYWORDS .

SOURCE Escherichia coli K12

ORGANISM Escherichia coli K12

Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales; Enterobacteriaceae; Escherichia.

REFERENCE 1 (bases 1 to 10401)

AUTHORS Blattner, F.R., Plunkett, G. III, Bloch, C.A., Perna, N.T., Burland, V., Riley, M., Collado-Vides, J., Glasner, J.D., Rode, C.K., Mayhew, G.F., Gregor, J., Davis, N.W., Kirkpatrick, H.A., Goeden, M.A., Rose, D.J., Mau, B. and Shao, Y.

TITLE The complete genome sequence of Escherichia coli K-12

JOURNAL Science 277 (5331), 1453-1474 (1997)

PUBMED 9278503

REFERENCE 2 (bases 1 to 10401)

AUTHORS Blattner, F.R.

TITLE Direct Submission

JOURNAL Submitted (16-JAN-1997) Guy Plunkett III, Laboratory of Genetics, University of Wisconsin, 445 Henry Mall, Madison, WI 53706, USA. Email: ecoli@genetics.wisc.edu Phone: 608-262-2534 Fax: 608-263-7459

REFERENCE 3 (bases 1 to 10401)

AUTHORS Blattner, F.R.

TITLE Direct Submission

JOURNAL Submitted (02-SEP-1997) Guy Plunkett III, Laboratory of Genetics, University of Wisconsin, 445 Henry Mall, Madison, WI 53706, USA. Email: ecoli@genetics.wisc.edu Phone: 608-262-2534 Fax: 608-263-7459

REFERENCE 4 (bases 1 to 10401)

AUTHORS Plunkett, G. III.

TITLE Direct Submission

JOURNAL Submitted (13-OCT-1998) Laboratory of Genetics, University of Wisconsin, 445 Henry Mall, Madison, WI 53706, USA

COMMENT On Sep 9, 1997 this sequence version replaced [gi:1789000](#). This sequence was determined by the E. coli Genome Project at the University of Wisconsin-Madison (Frederick R. Blattner, director). Supported by NIH grants HG00301 and HG01428 (from the Human Genome Project and NCHGR). The entire sequence was independently determined from E. coli K12 strain MG1655. Predicted open reading frames were determined using GeneMark software, kindly supplied by Mark Borodovsky, Georgia Institute of Technology, Atlanta, GA, 30332 [e-mail: mark@amher.gatech.edu]. Open reading frames that have been correlated with genetic loci are being annotated with CG Site Nos., unique ID nos. for the genes in the E. coli Genetic Stock Center (CGSC) database at Yale University, kindly supplied by Mary Berlyn. A public version of the database is accessible (<http://cgsc.biology.yale.edu>). Annotation of the genome is an ongoing task whose goal is to make the genome sequence more useful by correlating it with other data. Comments to the authors are appreciated. Updated information will be available at the E. coli Genome Project's World Wide Web site (<http://www.genetics.wisc.edu>). *** The E. coli K12 sequence and its annotations are periodically updated; this is version M54. No sequence changes. Annotation updates: updated gene identifications and products; all new functional assignments courtesy of Monica

Riley; added promoters, protein binding sites, and repeated sequences described in reference 1. The unique numeric identifiers beginning with a lowercase 'b' assigned to each gene (protein- or RNA-encoding) are now designated as gene synonyms instead of labels. This should allow them to be searched for in Entrez as gene names.

FEATURES	Location/Qualifiers
source	1..10401 /organism="Escherichia coli K12" /mol_type="genomic DNA" /strain="K12" /sub_strain="MG1655" /db_xref="taxon:83333"
gene	complement(212..4921) /gene="ypjA" /note="synonym: b2647"
CDS	complement(212..4921) /gene="ypjA" /function="putative transport; Not classified" /note="f1569; This 1569 aa ORF is 42 pct identical (65 gaps) to 883 residues of an approx. 864 aa protein YEJO_ECOLI SW: P33924; wasORF_f949 of GenBank Accession Number U36840" /codon_start=1 /transl_table=11 /product="putative ATP-binding component of a transport system" /protein_id="AAC75695.1" /db_xref="GI:1789001" /translation="MNTIHLRCLFRMPLVWCLWADVAALKRLSKRYSVFTFQRMKFM NRTSPYYCRRSVLSLLISALIYAPPGMAAFTTNVIGVVNDETVDGNQKVDERGTTNNT HIINHGGQNVHGGVSNGLIESGGYQDIGSHNNFVGQANNTTNGGRQSIHDGGISTG TTIESGNQDVYKGGISNGTTIKGGASRVEGGSANGILIDGGSQIVKVQGHADGTTINK SGSQDVVQGSLATNTTNGGRQYVEQSTVETTTIKNGGEQRYVESRALDRTIEGGTQS LNSKSTAKNTHIYSGGTQIVDNTSTSDVIEVYSGGVLDVRGGTATNVTQHDGAILKTN TNGTTVSGTNSGAFSIHNVADNVLLENGGLDINAYGSANKTIKDKGTMSVLNTNA KADATRIDNGGVM DVAGNATNTIINGGTQNNINNYGIATGTNINSGTQNIKSGGKADTT IISGSRQVVEKDGTAIGSNISAGGSLIVYTGGAHGVNQETGSALVANTGAGTDIEG YNKLSHFTITGGEANYVVLNTGELTVVAKTSKNTTIDTGGKLIVQKEAKTDSTRLN NGGVLEVQDGGEAKHVEQQSGGALIASTTSGTLIEGTNSYGDIFYIRNSEAKNVVLEN AGSLTVVTGSRVADTIINANGKMDVYKDVGTVLNSAGTQTIYASATSDKANIKGGKQ TVYGLATEANIESGEQIVDGGSTEKTHINGGTQTVQNYKKAINTDIVSGLQQIMANGT AEGSIINGGSQVVNEGGLAENSVLNDGGTLDVREKGSATGIQSSQALVATTRATRV TGTRADGVAFSIEQGAANNILLANGGVLTVESDTSSDKTQVNMGGREIVTKATATGT TLTGGEQIVEGVANETTINDGGIQTVSANGEAIKTKINEGGTLTVNDNGKATDIVQNS GAALQSTANGIEISGTHQYGTFSISGNLATNM LLENGGNLLVLAGEARDSTVVGKG AMQNLGQDSATKVNSGGQYTLGRSKDEFQALARAEDLVAGGTAIVYAGTLADASVSG ATGSLSLMTPRDNVT PVKLEGAVRITDSATLT LGNGVDTTLADLTAA SRGSVWLN SCAGTSNCEYRVNSLLNDGDVYLSAQTAAPATNGIYNTLTNNELSGSGNFYLTNTV AGSRGDQLVVNNNATGNFKIFVQDTGVSPQSDDAMTLVKTGGGDASFTLGNTGGFVDL GTYYEVLKSDGNSNWNLTNDVKPNPDPIPNPKPDKPKDPDPNPKPDPTPDPTPTPV PEKRITPSTAAVLNMAATLPLVFDALNSIRERLNMKASPHNNNVWGATYNTNRNNTV TDAGAGFEQTLTGMTVIGIDSRNDIPEGITTLGAFMGYSHSHIGFDRGGHGSVGSYSLG GYASWEHESGFYLDGVVKLNRFKSNVAGKMSSGGAANGSYHSNGLGGHIETGMRFTDG NWNLTYPYASLTGFTADNPEYHLSNGMKSVDTRSIIYRELGATLSYNNRLNGMEVEP WLKAAVRKEFVDDNRVKVNSDGNFVNYLSGRRGIYQAGIKASFSSTLSGHLGVGYSHS AGVESPWNAVAGVWNSF"
promoter	complement(4939..4968) /note="factor Sigma70; predicted +1 start at 2780887"
promoter	complement(4950..4976) /note="factor Sigma70; predicted +1 start at 2780898"
promoter	complement(4997..5024) /note="factor Sigma70; predicted +1 start at 2780945"
promoter	complement(5029..5058) /note="factor Sigma70; predicted +1 start at 2780977"
promoter	complement(5058..5086) /note="factor Sigma70; predicted +1 start at 2781006"
promoter	complement(5074..5103) /note="factor Sigma70; predicted +1 start at 2781022"
gene	complement(5130..5273) /gene="b2648"
CDS	complement(5130..5273) /gene="b2648" /function="orf; Unknown" /note="f47; This 47 aa ORF is 76 pct identical (0 gaps) to 25 residues of an approx. 192 aa protein DNIV_ECOLI SW: P03014; phage stats" /codon_start=1

```

/transl_table=11
/product="orf, hypothetical protein"
/protein_id="AAC75696.1"
/db_xref="GI:1789002"
/translation="MWHLVVLLEELCERGINFRALAQSIFAQQWGDECCKSKTICDLK
VIV"
promoter complement(5422..5453)
/Note="factor Sigma70; predicted +1 start at 2781370"
gene complement(5703..6494)
/ gene="b2649"
CDS complement(5703..6494)
/ gene="b2649"
/function="orf; Unknown"
/Note="f263; This 263 aa ORF is 26 pct identical (20 gaps)
to 167 residues of an approx. 1640 aa protein MSAP_PLAFW
SW: P04933; phagestats"
/codon_start=1
/transl_table=11
/product="orf, hypothetical protein"
/protein_id="AAC75697.1"
/db_xref="GI:1789003"
/translation="MESRNSYENKIDEISSLESKEHPIDIQEKKDAFVNEFKGVLF
DNTRRSSELLNFYECCKYKFLPRAQPDKIDSYNSALQAFSIFCSSTLTHNNIGFDFKL
FPEVKLSGEHLETVFKYKNGDDVREIAKINITLQKEGGGLYNLRGLDFKGCFFSGQNF
SNYDIQYVNWGTSLFDVDTPCIFNAPAYNKSNEKSLKPVSENGLSGVLTRNNKIKLI
TGVAFFDDILFMDDDFDSSSEDDPVENSPVVTSPVVSSSKSSFQ"
promoter complement(6523..6552)
/Note="factor Sigma70; predicted +1 start at 2782471"
gene complement(6594..7076)
/ gene="b2650"
CDS complement(6594..7076)
/ gene="b2650"
/function="orf; Unknown"
/Note="f160"
/codon_start=1
/transl_table=11
/product="orf, hypothetical protein"
/protein_id="AAC75698.1"
/db_xref="GI:1789004"
/translation="MLVSKSNGFNASAVLGSGSYNENKSSKHMELLAHSILKLICKEA
ASETYRGALETLOKMMSECIYQEGNAFVIMGAGEQLKRIKYEVGENNLLKVFNVHFNNN
HELVSSEGPDVICLSKQVWENLLIKLLENNENVFSETKKLSNKNADQFFECAKRNE"
promoter complement(7134..7161)
/Note="factor Sigma70; predicted +1 start at 2783082"
promoter 7182..7210
/Note="factor Sigma70; predicted +1 start at 2783172"
gene 7286..7417
/ gene="b2651"
CDS 7286..7417
/ gene="b2651"
/function="orf; Unknown"
/Note="o43; C-terminal differs from earlier version"
/codon_start=1
/transl_table=11
/product="orf, hypothetical protein"
/protein_id="AAC75699.1"
/db_xref="GI:2367148"
/translation="MKIVFQVLEIYISIALVNEHSHAPVTLTKLICLRRVFWVVDV"
gene complement(7827..7902)
/ gene="ileY"
/Note="synonym: b2652"
tRNA complement(7827..7902)
/ gene="ileY"
/product="tRNA-Ile"
/Note="anticodon: CAU; copy of ileX, except that
C6:G67base pair in aminoacyl stem is changed to A6:T67"
/function="RNA; tRNA"
gene complement(7865..8038)
/ gene="b2653"
CDS complement(7865..8038)
/ gene="b2653"
/function="orf; Unknown"
/Note="f57; This 57 aa ORF is 24 pct identical (0 gaps)
to 37 residues of an approx. 544 aa protein FIXN_AGRU SW:
P98055"
/codon_start=1
/transl_table=11
/product="orf, hypothetical protein"

```


/protein_id="AAC75700.1"
/db_xref="GI:1789006"
/translation="MEAVSGFMSRVITTQGEWERIKICYLHHMIIMFIAWFISIVIAH
SRPFSSVVRAGDS"
promoter complement(8183..8211)
/note="factor Sigma70; predicted +1 start at 2784131"
promoter 8316..8344
/note="factor Sigma70; predicted +1 start at 2784306"
gene 8462..8794
/gene="b2654"
CDS 8462..8794
/gene="b2654"
/function="orf; Unknown"
/note="o110; phage stats; This 110 aa ORF is 31 pct
identical (2 gaps) to 83 residues of an approx. 384 aa
protein RMAR WILMR SW:P47906"
/codon_start=1
/transl_table=11
/product="orf, hypothetical protein"
/protein_id="AAC75701.1"
/db_xref="GI:1789007"
/translation="MFSIKPGPRNLPIDNPILLSWNITDGDLSKLNLTLEYLNCITNI
INSCGVYPQGLKDREIISTFHAEKVINDLLKNDYKISLSPTTYRELNKAQRSITAP
DRIGERKT"
gene 8813..9307
/gene="b2655"
CDS 8813..9307
/gene="b2655"
/function="orf; Unknown"
/note="o164; o164; phage stats; This 164 aa ORF is 30 pct
identical (4 gaps) to 73 residues of an approx. 488 aa
protein YJQ2_YEAST SW:P46997"
/codon_start=1
/transl_table=11
/product="orf, hypothetical protein"
/protein_id="AAC75702.1"
/db_xref="GI:1789008"
/translation="MIERGDNSGVYQYGRAEHFTHIISDKPSPKDKYVAYAINIPDYE
LAADVYNINVTSPSGQQETFKILINLEHLRQTLEKSLTAVQKSQCEIITPKKPGEI
LHAFNATYQQIRENMSEFARCHYGYIQIPVTTFRVRTRNSRRRKGLLVSLSTRRS
LYHP"
gene 9312..9500
/gene="b2656"
CDS 9312..9500
/gene="b2656"
/function="orf; Unknown"
/note="o62; o62; phage stats; This 62 aa ORF is 29 pct
identical (0 gaps) to 47 residues of an approx. 472 aa
protein AMY1_AERHY SW:P22630"
/codon_start=1
/transl_table=11
/product="orf, hypothetical protein"
/protein_id="AAC75703.1"
/db_xref="GI:1789009"
/translation="MGDLQDFIALVKDAKKFGIDIIPDYTFNFMGIGSGKNDLDYPS
ADIRAKISKDIEGGIPGY"
protein bind 9379..9396
/gene="b2656"
/note="central position to predicted promoter: -233"
/bound_moiety="PhoB predicted site"
promoter 9583..9615
/note="factor Sigma70; predicted +1 start at 2785577"
gene 9672..10304
/gene="b2657"
CDS 9672..10304
/gene="b2657"
/function="putative enzyme; Not classified"
/note="o210; o210; phage stats; This 210 aa ORF is 28 pct
identical (19 gaps) to 187 residues of an approx. 472 aa
protein AMY1_AERHY SW:P22630"
/codon_start=1
/transl_table=11
/product="putative enzyme"
/protein_id="AAC75704.1"
/db_xref="GI:1789010"
/translation="MPKTPKSDQVIMLQNQYVREMRKYGVRGLRYDAAKHSKHEQIE
RSITPPLKNYNERLHNTNLFNPKYHKKAVMNYMEYLVTCQLDEQQMSLLYERDDL
SADFSLMKTIKAFSFGDLQTLASKPGSTISSIPERRILININHDFFNNGNLNDFDL

promoter FNHQDEQLAMAYIAALPFSRPLVYWDGQVLKSTTEIKNYDGSTRVGGEA"
10315..10342
/note="factor Sigma70; predicted +1 start at 2786304"
promoter 10401..>10401
/note="factor Sigma70; predicted +1 start at 2786391"

ORIGIN

```
1 atcaattttaa caacaagtta cacaaccaat tcagactccg ccagcccacc aatcatgatt
61 ggacggtgta aggacaacac caacaaaaac aggaagttag aagtctcagc aaaacaccga
121 ccagacggtg aggagacata aaaggatacg caaaggagcc gcggctcctg gtaacatgaa
181 agcccacaga tgtgggcttt ttogttgatg gtcagaacga ccagttcaca ccagctaccg
241 cggtccacgg ggattccaca ccggcactat ggctataccc caccccaaga tgcccgttta
301 acgtactgct gaatgaggct ttaatacctg cctgggtatat tccacgtctg cccgacaaat
361 aattgacgaa attaccgtca ctattcactt tcacccggtt atcatcgaca aattctttgc
421 gcacagcgcg cttcagccac ggctcaactt ccataccggt cccagacgcg atgttgtaac
481 tcagcgttgc gccaggttca cgatatatac tgcgggtatc gactgatttc gatttcattg
541 cattggataa atgatatcgg ggtttatcag cgggtgaacc cggttaacgat gcatacggcg
601 tcaggttcca gttaccatcg gtaaatacga tcccggttcc aatgtgaccg cccagcccgt
661 tgctgtggta actgccattg cgggctccac cgctgctcat ttacctgct acgttacttt
721 taaaacgggt cagcttcacg acaccgtcca gatagaaacc actttcatgt tcccaactgg
781 catagccgcc cagagaataa ctgcccacac tgccatgtcc tcccgcatca aaaccgatat
841 gtgaatggga atagcccata aaagcgccta gcgtggtaat tccttcagga atatcattac
901 ggctgtcgat ccccatgtgc attccgggtc gcgtctgtct aaacccggca cccgcatcgg
961 tgggtgacatt attacgggtg ttatacgtcg ccccccagac attattgttg tgtggactcg
1021 ctttcattat gttcaaccgc tcgcgaatac tgtttagctc agcatcaaat accaacggta
1081 atgttgctgc catattgagt acggctgccg tagaaggcgt aatgcgtttc tccggaacgg
1141 gtgtcggcgt tggatcggga gtagggtctg gttttggatt tgggtctggc tttggatcgg
1201 gttttgggtc gctccttggg tttgggatgg ggtccgggtt ggttttgaca tcattgggtc
1261 gggtccagtt gctgttgccg tcacttttca ggacatactc ataggtccca agatcaacga
1321 aaccgccggg attgcccagc gtaaacgaag catcccctcc cctgttttcc accagcgtca
1381 tcgcgtcgct agactgtggg ctgacgcggg tatcctgaac aaagatttta aaattaccag
1441 ttgcggttgtt gttgacgacc agttgatcgc cccgggagcc tgcaacgttg gtatgcaggt
1501 agaaattacc gctaccggaa agttcattgg ttgtcagcgt attgtagata ccgttagttg
1561 tggcaggcgc tgcgttttgt gctgacaaat aaacatcacc gtcgttgagt agcaaaactgt
1621 ttactctata ttgcagttg ctggtacctg cacaggaatt attgctggtt agccagacac
1681 tgcccgggct ggacgcgct aggtcggcaa gcgtggtatc gacgccattt cccagagtca
1741 atgtcgcgct atcggtaatc cggacgcgcc ctgcagttt aactggcgta acattatccc
1801 gtggcgctcat taacgacagg cttcctgtcg cgccactgac cgatgcatcc gccagcgtac
1861 ctgcgtagac gattgccgta ccgcagcgca cctggagatc ttctgcccgg gccagagcct
1921 gaaactcatc ttttgaccgc ccaagggtat attgcccgc agagttaacc tttgtggcgg
1981 agtctgacc caggttttgc attgcccac ccttgccaac cgtggagtgc cgagcttcgg
2041 tacctgctaa taccataaaa ttaccgcat tttccagcaa catattggtc gctaaattgc
2101 cggaattgga aaaaagtacc tactggtgag taccgctgat ttcaataacc ttagccgtgc
2161 tcgtctggag agcgcaccg ctgttctgga cgatatctgt cgctttgcca ttatcgttga
2221 ctgtcagcgt accgccttca ttgatctttg tttttattgc ctctcgttta gctgaaactg
2281 tttgtatttc gccgtcggtt attgttgtct cttcgcac accctcgaca attgttcac
2341 cgccggtgag cgtcgtgcct gtcgcagtg gctttgtttt gacgatctcc cgtccgcca
2401 tattgacctg tgttttgtca gaagaggtgt ctgactccac ggttaacacg ccgccatttg
2461 ccagcaggat attgttcgcc gcaccctgct cgatgctgaa cgcgacgcca tccgcgcgtg
2521 ttccgtgtac ccgcgtcgcc ctggtggttg caaccaaagc cgagtgtgcc gccgtcatta agcaccgagt
2581 ctcaccgttg cgtgcctttc tcccgcacat cgagtgtgcc attaataatg gaaccttcg
2641 tttcagccag gccgccttca ttaactacct gtgaaccccc ataatatgt gaaccttcg
2701 ctgtcccgtt tgccataatt tgttgtaggc cagagacgat atcggtattg attgccttac
2761 caaattctg aacggtttgc gtgccaccat tgatgtgtgt tttctctgtt gaccaccat
2821 cataaatttg ttccaccatt tcgatatatt cttcagtggc taaaccatat accgtttgtt
2881 tgccaccttt gatatttgct ttatcagaag tggcactggc atatatgtt tgggtgccag
2941 cactattgag tacagtgcga acatcttttc cataaacatc cattttgccg ttggcattaa
3001 taatcgtgtc aactgcgcgg gaaccagtga cgactgttaa tgagccagcg ttttccagca
3061 ctacattttt agcttctgaa ttctctgatg agaaagcatc accataactg ttggttcctt
3121 cgataagtgt tccggaggtc gtggaagcaa ttaatgcgcc gccggttgtt tgctcaacat
3181 gcttagcctc accaccgtcc tgaacctcca gaacgcgcgc attattaagt ctggtgctat
3241 ctggttttag ctccttctgg acaatcagct taccgccagt atcaatggta gtatttttctg
3301 cggagggttt agccactacc gtcagttcgc cggtattttc cagcacaca taattagcct
3361 cccctccggt aatagtgaag tgagagagct tgttgtatcc ttcgatatca gtccctgcac
3421 ccgtgttggt aactaaagca ctgcccgtct cctggttaac cccatgtgca ataccgcgg
3481 tatagacaat cagcagccct ccggcgctaa tattgtgcgc aattgcccgt ccatctttct
3541 caacaacctg ccggctcccc gaggatataa ttgttgtgtc agctttcccg ccgcttttga
3601 tattttgcgt tccgctgttg atattgtgct ctgtggctat gccataatta ttaatatctt
3661 gtgtgccacc attaatatg gtatttgtcg cgttttctgc tggttaaaac tgacattgtt cctttatctt
3721 tatctattcg ggtcgcatca gcttttagcat tggttaaaac tgacattgtt cctttatctt
3781 taataatcgt cttgtttgcc gaaccatatg cgtttatgtc taaatgacca ccgttttcca
3841 gcaacacatt gtctgccagc tgattgtgga tggagaatgc accttacta ttcgtaccgc
3901 tcaaccgtcg accgttagtg ttagttttta aaattgcacc atcgtgctgg gtaacatttg
3961 ttgccgtacc acccctaaca tcaagcacgc caccagaata aacttcaata acatccgagg
4021 tgctggtgtt atcaacaatt tgcgtgccac cagaatagat atgcgtattt tttgccgttg
4081 acttactatt cagagactga gttccgcctt caatcgtcgt gtccagcgca cggctctcat
4141 actacttttg ctcaccgcca tttttaatgg ttgtgttttc tactgtgctc tgttcaacat
4201 actgtcgacc accatttatg gttgtgttcg ttgccagact tcctgtact acgtcctgag
4261 agccagactt atttatcgtt gtaccatcag catgcccttg aacttttact atctggctac
```

4321 caccatcaat gagtattcca ttgcactcc ctccctctac gogtgaagca cgcgccctaa
4381 ttgtcgttcc attgctgata ccccttttat aaacgtcctg attgccactc tcgattgtcg
4441 tacctgtgga aatacccccg tcatgaattg actgtctgcc accgttaatg gttgtattat
4501 tagcctgccc cacaaaattg ttatgacttc ctatatcttg atatccacca gattcaataa
4561 gacttccatt agataccccg ccatgaacat tctgtctggc atggttgata atatgagtgt
4621 tatttgttgt acctcgttca tccacttttt ggttgccatc tacagtctca tcgtttacca
4681 caccaataac attagtagtg aaggcagcca tcccgggchg ggcataatc aaggcagata
4741 tcaataagga aagtactgag cggcgacaat aatagggact ggtcctgttc ataaatttca
4801 tccctgaaa agtgaatact gagtagcggt taagcgacct tagctttgct gcaacatcag
4861 cccacaggca ccagaccagg ggattcatcc tgaagagaca gcgcaagtgt attgtgttca
4921 ccgctcatca aagacatcat gatgaaatga tgatattccg cataagaatg aggcattttt
4981 taaacgcagt gcgctgaagt gtggttggtat aaaaaagtca atccattcag gaaatcggg
5041 cgtattcttt tctttcgaca atgagccgtt gccaaaataa aatgatttac ataactgttt
5101 ctgatgaata tcttctgctc acataaaaat cacacaataa ctttgagatc gcagattgtt
5161 ttacttttca agcattcgct cccccattgt tgggcaaata tagattgggc cagagcacga
5221 aagttaatac caggttcgca cagctcctcc aacagcacga caagatgcc aatactgcgc
5281 cccagtcggt tcagtttaca gactagcagt gcgttccctg ccgatgatgt cctgaccagt
5341 tttttcagtc cggacctcct gccacggtt tacgttgaag tggtaacct gagcacgcag
5401 ttcttcagtc aggcgtgggt caccgtaacg ctgttattgc tgggtaagat caaaaaactt
5461 tcaggcagct aaggaaagtt gaaccagaca ttagatgaaa ttttcaacc aattacagca
5521 ccaattcagt cactgccagc ccacaaaata aatcaagggt ttacatgaaa acgtagcccc
5581 tttttctttg gtatgacac taaaatggat gtagtgtgaa gaataatccc gttactcaa
5641 tcaataatca atattgttct aatctacgtt attatctctt tgtaaaaaat gccatttatt
5701 aatcattgaa aactgctttt agaacttgat acaacgggac tagtcacaac aggactattc
5761 tcaacgggat catcctcaga ggaactatca tcaagtcac catccataaa taaaatatca
5821 tcgaatgggt ccacgccgt gatgagtttt attttattat tacgatcagt caatactcca
5881 cttaaacagt tttcgtcac aggttttcat gatttttcat tactctgtt gtaagcaggc
5941 gcattaaaaa tacacggagt atcaacatca aacaatgacg ttcccaggt cacattattga
6001 atatcatagt tactgaagt ctgtccagaa aagaagcacc ccttaaaatc caatccacgt
6061 aaattatata aaccaccctc ttctttttgg agagtaatgt taattttggc tatctcccg
6121 acatcatcgc cattttttgta tttgaatacc gtttcaagat gttctccaga cagcttgact
6181 tcaggaaaata atttgaaatc aaagcctata ttattatgtg tcaacgtaga tgaacaaaaa
6241 atggaaaaag cttgcagtcg tgaattatag ctatcgattt tatcttgagg ctgagctctt
6301 ggtaaaaaact tatagcaaca ctcataaaaa gctctgaaga ccttgatttt
6361 ttatcaataa ataccacct gaactcattc acaaacgcac ctttttttct tgaatatct
6421 atggggtgtt cctttgactc tgacaagatg gaaatctcat ctattttgtt tcatatgaa
6481 ttacgtgatt ccatacacagc atttggcgcc gtttctaaaa taacactacg cgtactactt
6541 ggcttaagta aaccaacatg aaaaacactt tttcttatat tatcgaaaa gttctattca
6601 tttcttttag cgcattcaaa aaactgatcg gcattatttt tattcgataa ttttttagtt
6661 tcagaaaaca cattttcatt gttttccagc tttagtttaa tgagaagatt tcccagacc
6721 tgcttgctta aacatattac gtcaggtcca ccagaactaa ctaactcgtg attattatta
6781 aagtgtacgt tgaatacctt taagtatttt tcaccaactt catattttaa acgttttaat
6841 tgttctccag ctcccataat gacaaaaggc ttgcttctct gatataataa ttcagacatc
6901 attttttgta aagtttcaag agcacgcgga tacgtctctg atgcagcttc cttacaaatt
6961 aattttaaaa tactatgagc tagtagctcc atgtgtttag aagatttatt ttcattataa
7021 cttccactac ccaaaactgc gctagcgtaa aatccgttgc ttttactaac taacattgtc
7081 tattcctcaa ttaatgtcta catggctatt tttaatgtta ttactgtttg tcaactataa
7141 aaaacgctca tttgagacaa ttactgacat taactgcttc acttgctacg catggaactt
7201 ttaattaaat tagcacagga atgttaaatt taataaacia aaggttattt cgtgtatga
7261 taiaaaaaaac cgttataatt tattagttaa aatcgttttt caagtgttag aaatttatat
7321 ctcaatagcg ttggttaatg agcatagcca cgctcctgta acgctcacia aactcatctg
7381 cctcggcggt gtgttctggt cagtagtaga tgtttaaggc gtggcagaga catttcatcc
7441 ttactctacg gcattgttct acatacattg gttgtgttac tcacttatca tcagtgcgcg
7501 aacagagaat agttcagtgat tttgagtaat taacctgatt aaatgaagg gtataataaa
7561 tgataaatact ctggctttat cgttaattac ttaattcoac atgtaagcaa tttgcccgct
7621 tggcatagca ggcatttttt ccaggtaact ttgaatgagt actgatgat aaatacattg
7681 cagtggcggt ccacgtacca aaacaccagc cctcattcga aaccaccac cgcacttctt
7741 ccttgaaatg gcgttagtca tgaaatatag accgccatcg agtaccctt gtacccttaa
7801 ctcttctga tacgtaataa atgatttggt ggcccttgct ggacttgaac cagcgaccaa
7861 gcgattatga gtcgctgct ctaaccactg agctaaagg ccttgagtgt gcaataacaa
7921 tacttataaa ccacgcaata aacatgatga tcatatgat taaataacag atttttatgc
7981 tttccattc accttgggtc gtgattacac cgcacataaa acccgacac cctccattc
8041 gcaaaagtcga tactcgaggt caacaagcaa atgttaataa ttactctat ctatagttat
8101 catcgattca atgatacttt gtaatgattt tgtatctaata aataaactt tattacatta
8161 gctgaagagt tttcgatca ttatgatata tgttactttt cactccataa aaataaactt
8221 cgtatagcaa tatattcttt catagatctt attctgctaa tcattagttt cgtatgagcg
8281 atttttgaca gttgcctctc cagaccacat cgataaattaa taaaacagat ttaagcatta
8341 tctttttcca tataaatatt ggataaaaagt aggacatctg tttgcaatta ctttcacaa
8401 aattaaacat ttttatgttt cgtatataat catattactc taccattaga ggaactttat
8461 tatgttttct ataaaaccag gacccagaaa ttaacctatc gacaaccca cattgttatc
8521 atggaacatt actgacgggt atctaaattc caaattaaat acattagaat atctaaactg
8581 taaacaaatc attattaatt cttgtggagt ttacctcaa ggattaaaag acagagaaat
8641 tatatcaact tttcacgcag aaaaagttat taatgatctg ttaaaaaacg attataaaat
8701 ttocctttct ccagatacaa cttaccgaga gttgaataaa gcagcacagc gtgacattac
8761 agcgccagac aggataggag aaagaaaaac ataggtttat caacgagata caatgattga
8821 aagagtgat aacagcggtg tttatcagta tggctgctgt gaacatttca cccacattat
8881 atctgacaaa ccttcccaa aagataaata tgttgcatat gctattaaca ttcctgacta
8941 tgagctggca gccgatgtat ataataattaa cgtgacgtca cttccggac agcaagaaac

```
9001 attttaaata ttaatcaatc tagaacatct acggcaaaca cttgaacgta aatctcttac
9061 tgctgttcag aaatcacaat gtgaaatcat caccocaaa aaacctggcg aagcgattct
9121 tcatgctttt aatgccacct accagcagat cagagaaaa atgtctgaat ttgcacgttg
9181 ccattatggg tatatacaaa tccctccagt gacaactttc cgcgtccgac ggaccagaaa
9241 ctcccgaaga agaaaaggtt tactgggtttc atgcttatca acccgaagat ctttgtacca
9301 tccataatcc aatgggagat ttgcaggatt ttattgcatt gggttaaagat gctaaaaaat
9361 ttggtatcga tatcattcct gattatacct ttaactttat ggggaattggg ggtagtggta
9421 aaaatgacct ggattatccc tctgctgata tacgagcgaa gatcagtaaa gatatagaag
9481 gtggtatccc tggctattag caaggtcagg ttttgattcc attcattaaa gatccagtaa
9541 caaaagaacg taaacaaatc catccagaag atatacatct cactgcaaaa gacttcgaag
9601 caagtaaaga taacatctct aaggatgaat gggaaaacct ccatgcatta aaagaaaagc
9661 gtttaaattg aatgcctaaa acaacaccca aaagtgacca ggttattatg ttgcaaaatc
9721 aatacgttcg tgaatgcga aaatatggcg tacgaggttt acgttatgat gcggcaaac
9781 actcaaaaca tgaacaaata gaaagatcaa taacccacc gcttaaaaat tataatgagc
9841 ggttacacaa tactaactta tttaacccaa aatatcataa aaaagccgtt atgaattaca
9901 tggaatatct ggtaacttgt cagttggatg aacaacaaat gtcactactg ctttatgaaa
9961 gagatgattt aagcgccatt gatttttcat tgctcatgaa aacgataaaa gccttttcat
10021 ttggtggaga tcttcaaacc cttgcatcaa aaccgggttc cacaatctca agtatcccat
10081 cagaaagacg gatattgatt aacattaacc acgattttcc taacaatggg aatcttttca
10141 atgactttct atttaaccat caacaagatg aacaattagc aatggcatat atagccgctc
10201 tgccgttcag caggccttta gtttactggg atggccaagt attaaaatca acgactgaaa
10261 ttaaaaatta tgatgggtcc acgcgtgtcg gcggtgaggc gtagcttaat aaaggttgct
10321 ctacctatca gcagctctac aatgaattcc acgcattata tatagataaa gcaggaatat
10381 ggagcgcatt tgagggtgta t
```

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Aug 28 2007 16:53:42

ATTACHMENT C



My NCBI

[Sign in] [Register]

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Books

Search

CoreNucleotide

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

GenBank

Show

5

Send to

Hide:

☐

sequence

☐

all but gene, CDS and mRNA features

Range: from begin

to end

☐

Reverse complemented strand

Features:

+

Refresh

☐ 1: J01713. Reports E.coli tRNA opero...[gi:147952]

Links

Comment Features Sequence

LOCUS ECOTGOP 1100 bp DNA linear BCT 18-APR-1994

DEFINITION E.coli tRNA operon: supB-E tRNA gene cluster coding for 7 tRNAs.

ACCESSION J01713

VERSION J01713.1 GI:147952

KEYWORDS glnU gene; glnV gene; leuW gene; metT gene; supB region; supB-E transfer RNA operon; supE region; transfer RNA; transfer RNA-Gln; transfer RNA-Leu; transfer RNA-Met.

SOURCE Escherichia coli

ORGANISM Escherichia coli
Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales; Enterobacteriaceae; Escherichia.

REFERENCE 1 (bases 1 to 1100)

AUTHORS Nakajima,N., Ozeki,H. and Shimura,Y.

TITLE Organization and structure of an E. coli tRNA operon containing seven tRNA genes

JOURNAL Cell 23 (1), 239-249 (1981)

PUBMED 6163550

REFERENCE 2 (bases 897 to 899)

AUTHORS Nakajima,N., Ozeki,H. and Shimura,Y.

TITLE Organization and structure of an E. coli tRNA operon containing seven tRNA genes

JOURNAL Cell 25, 581-581 (1981)

REFERENCE 3 (sites)

AUTHORS Nakajima,N., Ozeki,H. and Shimura,Y.

TITLE In vitro transcription of the supB-E tRNA operon of Escherichia coli. Characterization of transcription products

JOURNAL J. Biol. Chem. 257 (18), 11113-11120 (1982)

PUBMED 6286682

REFERENCE 4 (bases 1 to 1100)

AUTHORS Ooi,T.

JOURNAL Unpublished (1983)

COMMENT Original source text: Escherichia coli DNA.
[2] correction to [1] in corrigendum.
[3] sites; transcription initiation and termination. [4] sent on tape from Kyoto University. Entry kindly reviewed by H.Ozeki (29-AUG-1984). The second tRNA, previously called 'X-tRNA', has been tentatively identified as Leu-tRNA.
All seven tRNAs are found on one primary transcript in vitro [1]. The DNA (bp 895-920) could form a hairpin structure of 12 bp, which is consistent with rho-independent termination sites. In the RNA termination site 'ctt' (bp 920-922) the first 't' is preferred (70%), the 'c' is second (22%) and the second 't' accounts for 5% of the RNA terminations [3].

FEATURES Location/Qualifiers

source 1..1100
/organism="Escherichia coli"
/mol_type="genomic DNA"
/db_xref="taxon:562"

misc RNA 151..920
/note="supB-E operon precursor RNA"

tRNA 184..260
/product="tRNA-Met"
/note="codon recognized: AUG"

tRNA 270..354
/product="tRNA-Leu"
/note="codon recognized: CUA"

tRNA 378..452
/product="tRNA-Gln"
/note="codon recognized: CAA"

tRNA 487..561
/product="tRNA-Gln"
/note="codon recognized: CCU"
tRNA 577..653
/product="tRNA-Met"
/note="codon recognized: CUA"
tRNA 701..775
/product="tRNA-Gln"
/note="codon recognized: CAG"
tRNA 813..887
/product="tRNA-Gln"
/note="codon recognized: AAU"

ORIGIN 113 bp upstream of HincII site; 15.5 min on K12 map.

```
1 atggctgtag ggtgggaaaa aacacaaagt aaacaataat tgacgaatat agcgccacgc
61 tgttcgcaac ctaaccaaac agtcactttc gagcaatttt ccttgaaaaa gaggttgacg
121 ctgcaaggct ctatacgcat aatgcgcccc gcaacgccga taaggatatc cgaaaaaaaa
181 gatggctacg tagctcagtt ggttagagca catcactcat aatgatgggg tcacagggtt
241 gaatccccgc gtatgccacca tctttttttg cgggagtggc gaaattggta gacgcaccag
301 atttaggttc tggcgccgca aggtgtgcga gttcaagtct cgctccccgc accattcacc
361 agaaagcggt gtacggatgg ggtatcgcca agcggttaagg caccggtttt tgataccggc
421 attccctggt tcgaatccag gtaccccagc catcttcttc gagtaagcgg ttcaccgccc
481 ggttattggg gtatcgccaa gcggttaagg accggttttt gataccggca ttccttggtt
541 cgaatccagg taccagcagc atcgaagaaa caatctggct acgtagctca gttggttaga
601 gcacatcact cataatgatg gggtcacagg ttcgaatccc gtcgtagcca ccaaattctg
661 aatgtatcga atatgttcgg caaattcaaa accaatttgt tggggtatcg ccaagcggta
721 aggcaccgga ttctgattcc ggcattccga ggttcgaatc ctctgacccc agccaattta
781 ttcaagacgc ttaccttgta agtgcaccca gttgggggat cgccaagcgg taaggcaccg
841 gattctgatt cgggcattcc gaggttcgaa tcctcgtagc ccagccacat taaaaaagct
901 cgcttcggcg agctttttgc ttttctgcgt tcattcaatg tcgaatgcga tgttgacacg
961 tcttatcctt caatgtcgga tgcgacgctg ccgctgttta tccgacctac ggttggcacg
1021 catccggcaa tgttgtaagg ctacaaccct aacgcataat tcagcgctg acgtttcaac
1081 acgccagcac gctccgcgcg
```

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Aug 28 2007 16:53:42

ATTACHMENT D



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#10

Application of: Cartens, Carsten-Peter

Serial No.: 09/492,590

Examiner: G. Leffers Jr.

Filed: January 27, 2000

Group: 1636

Entitled: METHODS AND COMPOSITIONS FOR
HIGH LEVEL EXPRESSION OF A
HETEROLOGOUS PROTEIN WITH POOR
CODON USAGE

RECEIVED
FEB 28 2001
TECH CENTER 1500-2500

Attorney Docket No.: 25436/1340 [Formerly 4114/85530]

Assistant Commissioner for Patents
Washington, D.C. 20231

RULE 132 DECLARATION OF MARY BUCHANAN

I, Mary Buchanan, hereby declare that:

1. I am employed by Stratagene, the assignee of record of the above-referenced patent application. I hold the position of Director of Product Management at Stratagene.

2. Stratagene's CodonPlusTM products contain tRNA genes corresponding to rarely used codons. Stratagene presently sells six different BL21-CodonPlusTM bacterial strains for use in enhancing the expression of protein encoded by genes containing rarely used codons. Bacterial strains BL21-CodonPlusTM RIL (Catalog # 230240), BL21-CodonPlusTM (DE3)-RIL (Catalog # 230245), and BL21-CodonPlus (DE3)-RIL-X (Catalog # 230265), are embodiments of the invention claimed in claims 1-12 and 37. Each of the above competent cell products contains three tRNA genes corresponding to rarely used codons consisting of argU, ileY, and leuW. Bacterial strains BL21-CodonPlusTM RP (Catalog # 230250), BL21-CodonPlusTM (DE3)-RP (Catalog # 230255), and BL21-CodonPlus(DE3)-RP-X (Catalog # 230275), are embodiments of

the invention claimed in claims 39-41 and 44. Each of the above competent cell products contains two tRNA genes corresponding to rarely used codons consisting of argU and proL.

CodonPlus™ host cell products were the first commercially available compositions to successfully allow high level expression of genes encoding rarely used codons. Sales figures provided below indicate the commercial success of these embodiments of the claimed invention (Table I). The products became available in May 1999 in the United States and continue to sell today.

Table I

<u>Year</u>	<u>Catalog #</u>	<u>Product</u>	<u>Number of tRNA genes</u>	<u>Date Introduced</u>	<u>Total Sales</u>
1999	230240	BL21-CodonPlus™-RIL Competent Cells	3	5/24/99	\$ 103,482
1999	230245	BL21-CodonPlus™(DE3)-RIL-Competent Cells	3	5/24/99	325,143
1999	230250	BL21-CodonPlus™-RP Competent Cells	2	8/27/99	18,764
1999	230255	BL21-CodonPlus™(DE3)-RP Competent Cells	2	8/27/99	46,052
1999 Total					493,441
2000	230240	BL21-CodonPlus™-RIL Competent Cells	3	5/24/99	59,265
2000	230245	BL21-CodonPlus™(DE3)-RIL Competent Cells	3	5/24/99	226,181
2000	230250	BL21-CodonPlus™-RP Competent Cells	2	8/27/99	51,210
2000	230255	BL21-CodonPlus™(DE3)-RP Competent Cells	2	8/27/99	144,118
2000	230265	BL21-CodonPlus™(DE3)-RIL-X Competent Cells	3	1/14/00	5,317
2000	230275	BL21-CodonPlus™(DE3)-RP-X Competent Cells	2	1/14/00	3,429
2000 Total					489,520
2001	230240	BL21-CodonPlus™-RIL Competent Cells	3	5/24/99	5,174
2001	230245	BL21-CodonPlus™(DE3)-RIL Competent Cells	3	5/24/99	17,230
2001	230250	BL21-CodonPlus™-RP Competent Cells	2	8/27/99	3,377
2001	230255	BL21-CodonPlus™(DE3)-RP Competent Cells	2	8/27/99	15,610
2001	230265	BL21-CodonPlus™(DE3)-RIL-X Competent Cells	3	1/14/00	162
2001	230275	BL21-CodonPlus™(DE3)-RP-X Competent Cells	2	1/14/00	162
2001 Total					41,715
TOTAL:					\$ 1,024,676

The primary reason one would use the CodonPlus™ series host cells is to increase the expression of genes containing low frequency codons. The CodonPlus™ series host cells are sold at \$195 per ml, which is 44.4% higher than the same competent cells without the array of tRNA genes (BL21, Catalog # 200133 and BL21 (DE3), Catalog # 200131). Essentially all of the customers who purchased the CodonPlus™ cells used them for the purpose of increasing the expression of heterologous genes encoding rarely used codons because there is no reason to use the more expensive CodonPlus host strains for routine expression of genes without low


frequency codon problems. Therefore, the commercial success of the CodonPlus™ series host cells is due to the presence of an array of two or three tRNA genes encoding rarely used codons.

3. The market for bacterial host cells is shared by a number of major companies, including Invitrogen, Promega, Novagen, and Life Technologies. The consumer is thus free to choose a product on the basis of objective principles. The commercial success Stratagene enjoyed in selling CodonPlus™ host cells is not the result of heavy promotion or advertising, nor the result of consumption by purchasers normally tied to Stratagene. Stratagene spent no more on promotion and advertising of the CodonPlus™ host cells than it did on any of the other new competent cell products it sells. For example, XL10-Gold® Ultracompetent cells (Catalog Nos. 200314, 200315 and 200317) were released in May 1997. Sales in 1997 were \$188,474 worldwide, \$592,193 in 1998. Launch costs were similar for both products.

4. I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

February 8, 2001

Date



Mary Buchanan

Director of Product Management

Stratagene

11011 North Torrey Pines Road

La Jolla, CA 92037

ATTACHMENT E

Attchd To Paper #15



Express Mail Label NO.: EL326923155US
Date of Deposit: November 9, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Carstens, Carsten-Peter

Serial No.: 09/492,590

Examiner: G. Leffers Jr.

Filed: January 27, 2000

Group: 1636

Entitled: METHODS AND COMPOSITIONS FOR
HIGH LEVEL EXPRESSION OF A
HETEROLOGOUS PROTEIN WITH POOR
CODON USAGE

Attorney Docket No.: 25436/1340 [Formerly 4114/85530]

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL DECLARATION OF MARY BUCHANAN

UNDER RULE 1.132

I, Mary Buchanan, hereby declare, supplemental to the Rule 1.132 Declaration filed on February 9, 2001, that:


1. I am employed by Stratagene, the assignee of record of the above-referenced patent application. I hold the position of Director of Product Management at Stratagene.

2. I understand that the Examiner has raised a question as to the relative level of sales of related products available in the marketplace upon which to base a comparison of the commercial success of the claimed host cell strains embodied in Stratagene's CodonPlus™ product line. The sales figures presented in my prior declaration encompassed Stratagene's sales over approximately 20 months from the first offer of sale in May of 1999 (BL21-CodonPlus™-RIL Competent Cells) to shortly before February 9, 2001. To my knowledge, prior to 2001, Stratagene held 100% of the market share for codon-enhanced host cells because there were no

other commercially available host cell strains containing recombinant genes for tRNAs specific for low-frequency codons (Novagen entered the market in early 2001 with their Rosetta™ strains). There would be no reason to buy or use the more expensive CodonPlus™ strains for the expression of genes without codon bias problems, so comparison of sales figures from other expression systems that are not codon optimized would not provide a meaningful background against which to determine commercial success.

3. I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

11/8/01
Date


Mary Buchanan
Director of Product Management
Stratagene
11011 North Torrey Pines Road
La Jolla, CA 92037